<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?covid-19-tdm?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">885699</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.885699</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis</article-title>
<alt-title alt-title-type="left-running-head">Lu et al.</alt-title>
<alt-title alt-title-type="right-running-head">Fluoropyrimidine-Related Coronary Disorders</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Yajie</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1215459/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deng</surname>
<given-names>Shizhou</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1721147/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dou</surname>
<given-names>Qiongyi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pan</surname>
<given-names>Wei</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Qingqing</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Hongchen</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xiaowen</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1689866/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Hong-Mei</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/966914/overview"/>
</contrib>
</contrib-group>
<aff>
<institution>Department of Clinical Oncology</institution>, <institution>Xijing Hospital</institution>, <institution>Air Force Medical University of PLA</institution>, <addr-line>Xi&#x2019;an</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/510666/overview">Ming-Ming Wu</ext-link>, Harbin Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/310688/overview">Massimiliano Berretta</ext-link>, University of Messina, Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1223498/overview">Takahiro Kogawa</ext-link>, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1374722/overview">Niansong Qian</ext-link>, Urumqi General Hospital of PLA, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Hong-Mei Zhang, <email>zhm@fmmu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>05</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>885699</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Lu, Deng, Dou, Pan, Liu, Ji, Wang and Zhang.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Lu, Deng, Dou, Pan, Liu, Ji, Wang and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Background:</bold> Coronary disorders are recognized as the most common manifestation of fluoropyrimidine-related cardiotoxicity in clinical practice. However, there are limited and conflicting data on the incidence and profiles of fluoropyrimidine-related coronary disorders. In this meta-analysis, we aimed to systematically assess the incidence of all-grade and grade 3 or higher fluoropyrimidine-related coronary disorders, and further explore the factors that influence its occurrence.</p>
<p>
<bold>Methods:</bold> Studies reporting the fluoropyrimidine-related coronary disorders were retrieved from a systematic search of English literature in the PubMed, Web of Science, Medline, and Cochrane database from 1 Jan 2001, to 1 Jan 2022. The NIH assessment tool was used to evaluate the quality of each study. The data of basic study characteristics, treatment details, and results of coronary toxicities were extracted. According to the results of the heterogeneity test (I<sup>2</sup> and <italic>p</italic>-value statistic), a random-effect model or fixed-effect model was selected for the pooled analysis of the incidence of adverse coronary events. Subgroup analysis was conducted to further explore the risks influencing the occurrence of fluoropyrimidine-related coronary disorders. The stability and publication bias of our results were evaluated by sensitivity analysis and Egger test, respectively.</p>
<p>
<bold>Results:</bold> A total of 63 studies were finally included in our pooled analysis, involving 25,577 patients. The pooled cumulative incidence of all-grade and grade 3 or higher coronary disorders was 2.75% (95% CI 1.89%&#x2013;3.76%) and 1.00% (95% CI 0.62%&#x2013;1.47%), respectively. The coronary disorders were most reported as myocardial ischemia (1.28%, 95% CI 0.42%&#x2013;2.49%) and angina/chest pain (1.1%, 95% CI 0.54%&#x2013;1.81%). Subgroup analysis revealed that studies in the female-only population seemed to have a lower incidence of fluoropyrimidine-related coronary disorders. The occurrence of adverse coronary events varied among different tumor types. Patients with esophageal cancer have the highest coronary toxicity (6.32%), while those with breast cancer have a relatively lower incidence (0.5%). Coronary disorders induced by 5-FU monotherapy are more frequent than that induced by capecitabine (3.31% vs. 1.21%, <italic>p</italic> &#x3c; 0.01). Fluoropyrimidine combination therapy, whether combined with other chemotherapy drugs, targeted therapy drugs, or radiotherapy, significantly increased the incidence of coronary complications (<italic>p</italic> &#x3c; 0.01).</p>
<p>
<bold>Conclusion:</bold> This meta-analysis has defined the incidence of fluoropyrimidine-related coronary disorders and depicted its epidemiological profiles for the first time, which may provide a reference for clinical practice in cancer management.</p>
</abstract>
<kwd-group>
<kwd>coronary disorder</kwd>
<kwd>5-FU</kwd>
<kwd>capecitabine</kwd>
<kwd>meta-analysis</kwd>
<kwd>fluoropyrimidine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>With the continuous development of chemotherapy, radiotherapy, and new treatment technologies, the survival of cancer patients has been greatly improved. Meanwhile, the cardiovascular toxicity related to anti-tumor therapy has become increasingly prominent, which is one of the important causes of death due to treatment-related complications (<xref ref-type="bibr" rid="B13">Curigliano et al., 2016</xref>). Cardio-Oncology, an emerging interdisciplinary field, focuses on cardiovascular disease in cancer patients, and has developed rapidly in recent years (<xref ref-type="bibr" rid="B47">Koutsoukis et al., 2018</xref>). The incidence and spectrum of cardiotoxicity vary widely by chemotherapeutic regimens. The cardiotoxicity of anthracyclines has been extensively studied and highly concerned over the past 2&#xa0;decades (<xref ref-type="bibr" rid="B55">Lotrionte et al., 2013</xref>; <xref ref-type="bibr" rid="B82">Smith et al., 2010</xref>). However, fluoropyrimidine (5-fluorouracil (5-FU), capecitabine, S-1, Tas102, etc.) induced cardiotoxicity has not been attracted equal attention.</p>
<p>The coronary disorder is one of the typical adverse reactions induced by chemotherapy agents, such as 5-FU and capecitabine, which often refers to the transient contraction of coronary artery and thrombus formation, causing varying degrees of myocardial ischemia, and resulting in the clinical syndrome of angina pectoris, myocardial infarction, even sudden death (<xref ref-type="bibr" rid="B66">More et al., 2021</xref>). Chest pain with typical or atypical angina pectoris is the most prominent manifestation of the coronary disorder, which has directly been visualized during coronary angiography (<xref ref-type="bibr" rid="B4">Baldeo et al., 2018</xref>; <xref ref-type="bibr" rid="B14">Das et al., 2019</xref>; <xref ref-type="bibr" rid="B24">Gao et al., 2019</xref>).</p>
<p>Despite some studies that have focused on fluoropyrimidine-induced coronary disorder, most of them were conducted with small samples or just case reports (<xref ref-type="bibr" rid="B41">Karakulak et al., 2016</xref>; <xref ref-type="bibr" rid="B7">Ben-Yakov et al., 2017</xref>; <xref ref-type="bibr" rid="B80">Sedhom et al., 2017</xref>). The reported incidence of fluoropyrimidine-related coronary disorder varies from 0% to 35% (<xref ref-type="bibr" rid="B71">Pai and Nahata, 2000</xref>; <xref ref-type="bibr" rid="B78">Sara et al., 2018</xref>; <xref ref-type="bibr" rid="B51">Lestuzzi et al., 2020</xref>), which is a too wide range to provide valuable reference for clinical practice. In addition, some studies suggested that the occurrence of coronary disorder depended on the different fluoropyrimidine drugs, route of administrations, dosage schedules, and co-administered agents (<xref ref-type="bibr" rid="B18">Depetris et al., 2018</xref>; <xref ref-type="bibr" rid="B40">Kanduri et al., 2019</xref>). However, there is no consensus on the incidence, profiles, and risk factors of fluoropyrimidine-related coronary disorders. An accurate description of the incidence and epidemiological characteristics of coronary vasospasm is the basis for guiding clinical practice and is very crucial for the early identification and prevention of ischemic events caused by fluoropyrimidines. Obviously, the currently available data are not yet sufficient for drawing definite conclusions. Therefore, in this systematic review and meta-analysis, we are dedicated to comprehensively and systematically evaluating the incidence and epidemiological characteristics of fluoropyrimidine-induced coronary disorders and to further exploring the factors influencing its occurrence using a method of single-rate meta-analysis.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>The Definition of Coronary Disorder</title>
<p>The coronary disorder of interest in this study was defined as a group of symptoms represented by chest pain syndrome, including angina pectoris, myocardial ischemia, myocardial infarction, and acute coronary syndrome. The fluoropyrimidine-related coronary disorders were recognized by the new occurrence of a chest pain at rest in the presence of recent fluoropyrimidine administration with or without electrocardiogram (ECG) or biomarker changes.</p>
</sec>
<sec id="s2-2">
<title>Search Strategy and Selection Criteria</title>
<p>Literature search and study selection were conducted under the PRISMA guidelines. Studies reporting the fluoropyrimidine-related coronary disorders were retrieved from a systematic search of English literature in the PubMed, Web of Science, Medline, and Cochrane database from 1 Jan 2001 to 1 Jan 2022. The search strategy was determined after several pre-retrievals and finally combined the following two sorts of items: 1) &#x201c;fluoropyrimidine&#x201d; OR &#x201c;5-FU&#x201d; OR &#x201c;capecitabine&#x201d; OR &#x201c;S-1&#x201d; OR &#x201c;Tas102&#x201d;; 2) &#x201c;cardiotoxicity&#x201d; OR &#x201c;coronary vasospasm&#x201d; OR &#x201c;chest pain&#x201d; OR &#x201c;angina&#x201d; OR &#x201c;myocardial ischemia&#x201d; OR &#x201c;myocardial infarction&#x201d; OR &#x201c;acute coronary syndrome.&#x201d; Studies had to meet the following inclusion criteria: 1) patients with a diagnosis of solid malignances; 2) articles explicitly reported the coronary disorders as defined above, and it is associated with fluorouracil-containing treatment; 3) the sample size was greater than 20; 4) the full-text was available; 5) prospective or retrospective clinical studies. Reviews, letters, comments, case report, meeting abstract were excluded.</p>
</sec>
<sec id="s2-3">
<title>Methodological Quality Assessment and Data Extraction</title>
<p>The quality of included studies was assessed using the quality assessment tool of the National Institutes of Health (NIH) (<xref ref-type="bibr" rid="B68">Nhlbi Study Quality Assessment Tools, 2020</xref>, <xref ref-type="sec" rid="s10">Supplementary Table S1</xref>). The reviewers could select &#x201c;YES,&#x201d; &#x201c;NO,&#x201d; or &#x201c;Cannot Determine/Not Applicable/Not Reported&#x201d; for each item in the list. Based on their responses, the quality of each study was graded as &#x201c;good,&#x201d; &#x201c;fair,&#x201d; or &#x201c;poor.&#x201d; The incidences of fluoropyrimidine-related coronary disorders of all-grade and grade 3 or higher were the main outcomes in this meta-analysis. The data of basic characteristics (first-author, publication year, study design, country or region, age, gender, tumor type, and sample size), treatment details (treatment type, line, regimen, and dosage), and the incidence of fluoropyrimidine-related coronary disorders were extracted and documented. Two authors (Lu and Deng) independently searched the literature, assessed the quality of included studies, and extracted and cross-checked the data.</p>
</sec>
<sec id="s2-4">
<title>Statistical Analysis</title>
<p>The incidence of fluoropyrimidine-related coronary disorders in each study was shown as a percentage calculated using a division method (<inline-formula id="inf1">
<mml:math id="m1">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>m</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>f</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>m</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>f</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mo>&#xa0;</mml:mo>
<mml:mi>p</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>s</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>&#xd7;</mml:mo>
<mml:mn>100</mml:mn>
<mml:mo>%</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>). The Cochran&#x2019;s chi-squared test reporting I<sup>2</sup> statistic and <italic>p</italic>-value was used to test heterogeneity, and if heterogeneity exists (I<sup>2</sup> &#x3e; 50% or <italic>p</italic> &#x3c; 0.1), a random-effect model was conducted, otherwise, a fixed-effect model was adopted. The pooled incidence was achieved by a single rate meta-analysis method, shown as a proportion and 95 confidence intervals (CI). Subgroup analyses were performed based on study-level characteristics (e.g., publication period, study design, gender, age, tumor, treatment type, regimen, and so on) for all-grade and grade 3 or higher adverse coronary events. Sensitivity analyses were conducted to evaluate the stability of our results. Publication bias was shown by funnel plot symmetry and statistically checked using the Egger test. For all tests, <italic>p</italic>-values less than 0.05 were considered statistically significant. All the statistical process of this meta-analysis was performed using R software (version 4.0.6, MathSoft, Massachusetts) with &#x201c;meta,&#x201d; &#x201c;rmeta,&#x201d; and &#x201c;metafor&#x201d; packages.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Eligible Studies and Characteristics</title>
<p>A total of 1818 initial records were identified through a literature search. After title and abstract screening and full-text screening, 63 studies were finally included in this meta-analysis, involving 25,577 patients (<xref ref-type="fig" rid="F1">Figure 1</xref>). The included populations covered more than 30 countries around the world, of which 5 were multi-country collaborations. Forty-seven (74.6%) of the 63 included articles were prospective studies, while the remaining 16 (25.4%) were retrospective in design. The tumor spectrum included colorectal cancer (number of studies: <italic>n</italic> &#x3d; 25, 39.7%), breast cancer (<italic>n</italic> &#x3d; 11, 17.5%), esophagus cancer (<italic>n</italic> &#x3d; 4, 6.3%), gastric cancer (<italic>n</italic> &#x3d; 3, 4.8%), and others (<italic>n</italic> &#x3d; 9, 14.3%), the remaining 11 (17.5%) studies focused on mixed solid malignancies without distinguishing specific tumor categories. The included 63 studies consisted of 92 treatment arms, and their regimens included 5-FU/capecitabine mono chemotherapy (<italic>n</italic> &#x3d; 20, 21.7%), 5-FU/capecitabine combined chemotherapy (<italic>n</italic> &#x3d; 33, 35.9%), 5-FU/capecitabine based chemotherapy plus targeted therapy (<italic>n</italic> &#x3d; 25, 27.2%), 5-FU/capecitabine based chemotherapy plus radiotherapy (<italic>n</italic> &#x3d; 6, 6.5%), and the modified fluoropyrimidine agents S1 or TAS 102 (<italic>n</italic> &#x3d; 2, 2.2%). According to the NIH quality assessment tools, 29 studies (46%) were rated as high quality, 34 (54%) fair quality, and none was classified as poor (high risk of bias). The detailed characteristics of each included study are shown in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The flow diagram for literature selection, screening, and inclusion.</p>
</caption>
<graphic xlink:href="fphar-13-885699-g001.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The characteristics of the included 64 studies.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">No</th>
<th align="center">Author</th>
<th align="center">Year</th>
<th align="center">Country/Region</th>
<th align="center">Sample size</th>
<th align="center">Study design</th>
<th align="center">Age</th>
<th align="center">Gender (female%)</th>
<th align="center">Tumor type</th>
<th align="center">Regimen</th>
<th align="center">Quality</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left">1</td>
<td rowspan="2" align="left">Zafar A</td>
<td rowspan="2" align="char" char=".">2021</td>
<td rowspan="2" align="left">United States</td>
<td rowspan="2" align="char" char=".">4,019</td>
<td rowspan="2" align="left">retro</td>
<td align="center">58 &#xb1; 13</td>
<td align="center">0.425</td>
<td rowspan="2" align="left">Mixed malignancies</td>
<td rowspan="2" align="left">5-FU or Cap based</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B93">Zafar et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">64 &#xb1; 13</td>
<td align="center">0.414</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">Mayer IA</td>
<td align="char" char=".">2021</td>
<td align="left">United States</td>
<td align="char" char=".">198</td>
<td align="left">pros</td>
<td align="center">52 (26&#x2013;76)</td>
<td align="center">1</td>
<td align="left">Breast cancer</td>
<td align="left">Cap</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B61">Mayer et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">3</td>
<td rowspan="2" align="left">Chakravarthy AB</td>
<td rowspan="2" align="char" char=".">2020</td>
<td rowspan="2" align="left">United States</td>
<td rowspan="2" align="char" char=".">355</td>
<td rowspan="2" align="left">pros</td>
<td align="center">54.3 &#xb1; 11.7</td>
<td align="center">0.348</td>
<td rowspan="2" align="left">Rectal cancer</td>
<td align="left">mFOLFOX</td>
<td rowspan="2" align="left">Fair</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B8">Chakravarthy et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">53.9 &#xb1; 9.9</td>
<td align="center">0.376</td>
<td align="left">mFOLFOX &#x2b; Bev</td>
</tr>
<tr>
<td rowspan="3" align="left">4</td>
<td rowspan="3" align="left">Dyhl-Polk A (1)</td>
<td rowspan="3" align="char" char=".">2020</td>
<td rowspan="3" align="left">Denmark</td>
<td rowspan="3" align="char" char=".">108</td>
<td rowspan="3" align="left">retro</td>
<td rowspan="3" align="center">66 (35&#x2013;81)</td>
<td rowspan="3" align="center">0.454</td>
<td rowspan="3" align="left">Colorectal or anal cancer</td>
<td align="left">Coloretal cancer: 5-Fu or FOLFOX</td>
<td rowspan="3" align="left">Fair</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B19">Dyhl-Polk et al. (2020a)</xref>
</td>
</tr>
<tr>
<td align="left">Metastatic: FOLFOX or FOLFIRI &#xb1; Cet or Pan</td>
</tr>
<tr>
<td align="left">Anal cancer: FP &#x2b; RT</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">Delaloge S</td>
<td align="char" char=".">2020</td>
<td align="left">Multi-country</td>
<td align="char" char=".">628</td>
<td align="left">pros</td>
<td align="center">18&#x2013;70</td>
<td align="center">1</td>
<td align="left">Breast cancer</td>
<td align="left">TX</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Delaloge et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">Grierson P</td>
<td align="char" char=".">2020</td>
<td align="left">United States</td>
<td align="char" char=".">16</td>
<td align="left">pros</td>
<td align="center">66 (42&#x2013;73)</td>
<td align="center">0.563</td>
<td align="left">Pancreatic ductal adenocarcinoma</td>
<td align="left">Cap &#x2b; Tosedostat</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B29">Grierson et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">7</td>
<td rowspan="2" align="left">Dyhl-Polk A (2)</td>
<td rowspan="2" align="char" char=".">2020</td>
<td rowspan="2" align="left">Denmark</td>
<td rowspan="2" align="char" char=".">2,236</td>
<td rowspan="2" align="left">retro</td>
<td align="center">65 (21&#x2013;85)</td>
<td align="center">0.447</td>
<td rowspan="2" align="left">Colorectal cancer</td>
<td align="left">5-FU based</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B20">Dyhl-Polk et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">70 (22&#x2013;93)</td>
<td align="center">0.471</td>
<td align="left">Cap based</td>
</tr>
<tr>
<td align="left">8</td>
<td align="left">Raber I</td>
<td align="char" char=".">2019</td>
<td align="left">United States</td>
<td align="char" char=".">177</td>
<td align="left">retro</td>
<td align="center">54&#x2013;77</td>
<td align="center">0.452</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-FU or Cap based</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B77">Raber et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">Jin X</td>
<td align="char" char=".">2019</td>
<td align="left">China</td>
<td align="char" char=".">129</td>
<td align="left">retro</td>
<td align="center">&#x3e;18</td>
<td align="center">0.217</td>
<td align="left">Gastric cancer</td>
<td align="left">5-FU or Cap or S-1 based</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B38">Jin et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">Primrose JN</td>
<td align="char" char=".">2019</td>
<td align="left">United Kingdom</td>
<td align="char" char=".">213</td>
<td align="left">pros</td>
<td align="center">62 (55&#x2013;68)</td>
<td align="center">0.5</td>
<td align="left">Biliary tract cancer</td>
<td align="left">Cap</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B76">Primrose et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">Abdel-Rahman O</td>
<td align="char" char=".">2019</td>
<td align="left">Canada</td>
<td align="char" char=".">3,223</td>
<td align="left">pros</td>
<td align="center">60.7 (11.4)</td>
<td align="center">0.403</td>
<td align="left">Colorectal cancer</td>
<td align="left">FOLFOX or 5-FU based &#x2b; Bev and/or Pan</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B1">Abdel-Rahman, (2019)</xref>
</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">Hayashi Y</td>
<td align="char" char=".">2019</td>
<td align="left">Japan</td>
<td align="char" char=".">80</td>
<td align="left">pros</td>
<td align="center">66.5 (62&#x2013;73)</td>
<td align="center">0.113</td>
<td align="left">Esophageal cancer</td>
<td align="left">5-FU/cisplatin &#x2b; RT</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B31">Hayashi et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">Peng J</td>
<td align="char" char=".">2018</td>
<td align="left">China</td>
<td align="char" char=".">527</td>
<td align="left">pros</td>
<td align="center">57 (23&#x2013;87)</td>
<td align="center">0.339</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-FU or Cap based</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B73">Peng et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">14</td>
<td align="left">Chen EY</td>
<td align="char" char=".">2018</td>
<td align="left">China</td>
<td align="char" char=".">47</td>
<td align="left">pros</td>
<td align="center">59.7 (21.4&#x2013;80.1)</td>
<td align="center">0.276</td>
<td align="left">Colorectal cancer</td>
<td align="left">FOLFIRI &#x2b; Celecoxib</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B9">Chen et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">Kwakman JJM</td>
<td align="char" char=".">2017</td>
<td align="left">Netherlands</td>
<td align="char" char=".">1973</td>
<td align="left">pros</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="left">Colorectal cancer</td>
<td align="left">Cap mono or based &#xb1; Bev</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B49">Kwakman et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">Turan T</td>
<td align="char" char=".">2017</td>
<td align="left">Turkey</td>
<td align="char" char=".">32</td>
<td align="left">pros</td>
<td align="center">57</td>
<td align="center">0.303</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-FU based</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B85">Turan et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">Leicher LW</td>
<td align="char" char=".">2017</td>
<td align="left">Netherland</td>
<td align="char" char=".">86</td>
<td align="left">retro</td>
<td align="center">69 (45&#x2013;83)</td>
<td align="center">0.523</td>
<td align="left">Colorectal cancer</td>
<td align="left">Cap</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B50">Leicher et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">18</td>
<td rowspan="2" align="left">Zhang P</td>
<td rowspan="2" align="char" char=".">2017</td>
<td rowspan="2" align="left">China</td>
<td rowspan="2" align="char" char=".">397</td>
<td rowspan="2" align="left">pros</td>
<td rowspan="2" align="center">25&#x2013;70</td>
<td rowspan="2" align="center">1</td>
<td rowspan="2" align="left">Breast cancer</td>
<td align="left">Cap &#x2b; Utidelone</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B94">Zhang et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">Cap</td>
</tr>
<tr>
<td rowspan="2" align="left">19</td>
<td rowspan="2" align="left">Kerr RS</td>
<td rowspan="2" align="char" char=".">2016</td>
<td rowspan="2" align="left">Multi-country</td>
<td rowspan="2" align="char" char=".">1941</td>
<td rowspan="2" align="left">pros</td>
<td rowspan="2" align="center">65 (58&#x2013;71)</td>
<td rowspan="2" align="center">0.427 0.429</td>
<td rowspan="2" align="left">Colorectal cancer</td>
<td align="left">Cap &#x2b; Bev</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B42">Kerr et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">Cap</td>
</tr>
<tr>
<td align="left">20</td>
<td align="left">Winther SB</td>
<td align="char" char=".">2016</td>
<td align="left">Norway</td>
<td align="char" char=".">71</td>
<td align="left">retro</td>
<td align="center">67&#x2013;87</td>
<td align="center">0.408</td>
<td align="left">Colorectal cancer</td>
<td align="left">SOX or S-1</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B89">Winther et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">21</td>
<td align="left">Polk A</td>
<td align="char" char=".">2016</td>
<td align="left">Denmark</td>
<td align="char" char=".">452</td>
<td align="left">retro</td>
<td align="center">63 (28&#x2013;88)</td>
<td align="center">1</td>
<td align="left">Breast cancer</td>
<td align="left">Cap &#x2b; Tra</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B75">Polk et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">22</td>
<td align="left">Mayer RJ</td>
<td align="char" char=".">2015</td>
<td align="left">United States</td>
<td align="char" char=".">534</td>
<td align="left">pros</td>
<td align="center">63 (27&#x2013;82)</td>
<td align="center">0.389</td>
<td align="left">Colorectal cancer</td>
<td align="left">TAS102</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B62">Mayer et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">23</td>
<td align="left">Lestuzzi C</td>
<td align="char" char=".">2014</td>
<td align="left">Germany</td>
<td align="char" char=".">358</td>
<td align="left">pros</td>
<td align="center">57.5 (23&#x2013;80)</td>
<td align="center">NA</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-FU or 5-FU based</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B52">Lestuzzi et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">24</td>
<td align="left">Tonyali O</td>
<td align="char" char=".">2013</td>
<td align="left">Turkey</td>
<td align="char" char=".">37</td>
<td align="left">retro</td>
<td align="center">46 (30&#x2013;75)</td>
<td align="center">1</td>
<td align="left">Breast cancer</td>
<td align="left">TX &#x2b; Tra</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B83">Tonyali et al. (2013)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">25</td>
<td rowspan="2" align="left">Okines AFC</td>
<td rowspan="2" align="char" char=".">2013</td>
<td rowspan="2" align="left">United Kingdom</td>
<td rowspan="2" align="char" char=".">120</td>
<td rowspan="2" align="left">pros</td>
<td align="center">62 (56&#x2013;67)</td>
<td align="center">0.321</td>
<td rowspan="2" align="left">Gastro-esophageal adenocarcinoma</td>
<td align="left">ECX</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B70">Okines et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="center">64 (56&#x2013;69)</td>
<td align="center">0.182</td>
<td align="left">ECX &#x2b; Bev</td>
</tr>
<tr>
<td align="left">26</td>
<td align="left">Khan MA</td>
<td align="char" char=".">2012</td>
<td align="left">Pakistani</td>
<td align="char" char=".">301</td>
<td align="left">retro</td>
<td align="center">47 (18&#x2013;81)</td>
<td align="center">0.249</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-FU or 5-FU/Cap based</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B43">Khan et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left">27</td>
<td align="left">Martin M</td>
<td align="char" char=".">2012</td>
<td align="left">Multi-country</td>
<td align="char" char=".">88</td>
<td align="left">Pros</td>
<td align="center">53 (32&#x2013;82)</td>
<td align="center">0.988</td>
<td align="left">Breast cancer</td>
<td align="left">Cap &#x2b; Bev &#x2b; Tra</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B59">Martin et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left">28</td>
<td align="left">Petrini L</td>
<td align="char" char=".">2012</td>
<td align="left">Italy</td>
<td align="char" char=".">39</td>
<td align="left">pros</td>
<td align="center">67 (41&#x2013;83)</td>
<td align="center">0.154</td>
<td align="left">Hepatocellular carcinoma</td>
<td align="left">5-FU &#x2b; Sorafenib</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B74">Petrini et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left">29</td>
<td align="left">Koca D</td>
<td align="char" char=".">2011</td>
<td align="left">Turkey</td>
<td align="char" char=".">52</td>
<td align="left">pros</td>
<td align="center">59</td>
<td align="center">0.75</td>
<td align="left">Mixed malignancies</td>
<td align="left">Cap or Cap based &#x2b; Lap</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B44">Koca et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">30</td>
<td align="left">Jensen SA</td>
<td align="char" char=".">2010</td>
<td align="left">Denmark</td>
<td align="char" char=".">106</td>
<td align="left">pros</td>
<td align="center">64 (37&#x2013;81)</td>
<td align="center">0.556</td>
<td align="left">Colorectal cancer</td>
<td align="left">FOLFOX4</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B36">Jensen et al. (2010)</xref>
</td>
</tr>
<tr>
<td align="left">31</td>
<td align="left">Masi G</td>
<td align="char" char=".">2010</td>
<td align="left">Italy</td>
<td align="char" char=".">57</td>
<td align="left">pros</td>
<td align="center">61 (34&#x2013;75)</td>
<td align="center">0.4</td>
<td align="left">Colorectal cancer</td>
<td align="left">FOLFOXIRI &#x2b; Bev</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B60">Masi et al. (2010)</xref>
</td>
</tr>
<tr>
<td align="left">32</td>
<td align="left">Michalaki V</td>
<td align="char" char=".">2010</td>
<td align="left">Greece</td>
<td align="char" char=".">29</td>
<td align="left">pros</td>
<td align="center">52 (34&#x2013;70)</td>
<td align="center">1</td>
<td align="left">Breast cancer</td>
<td align="left">TX &#x2b; Tra</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B64">Michalaki et al. (2010)</xref>
</td>
</tr>
<tr>
<td align="left">33</td>
<td align="left">Chua YJ</td>
<td align="char" char=".">2010</td>
<td align="left">Australia</td>
<td align="char" char=".">105</td>
<td align="left">pros</td>
<td align="center">64 (54&#x2013;70)</td>
<td align="center">0.46</td>
<td align="left">Rectal cancer</td>
<td align="left">XELOX</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B11">Chua et al. (2010)</xref>
</td>
</tr>
<tr>
<td align="left">34</td>
<td align="left">Baur M</td>
<td align="char" char=".">2010</td>
<td align="left">Austria</td>
<td align="char" char=".">71</td>
<td align="left">pros</td>
<td align="center">62 (39&#x2013;84)</td>
<td align="center">0.394</td>
<td align="left">Rectal cancer</td>
<td align="left">5-FU based</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B5">Baur et al. (2010)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">35</td>
<td rowspan="2" align="left">Joensuu H</td>
<td rowspan="2" align="char" char=".">2009</td>
<td rowspan="2" align="left">Multi-country</td>
<td rowspan="2" align="char" char=".">231</td>
<td rowspan="2" align="left">pros</td>
<td rowspan="2" align="center">&#x2264;65</td>
<td rowspan="2" align="center">1</td>
<td rowspan="2" align="left">Breast cancer</td>
<td align="left">5-FU based &#x2b; Tra</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B39">Joensuu et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="left">5-FU based</td>
</tr>
<tr>
<td rowspan="2" align="left">36</td>
<td rowspan="2" align="left">Skof E</td>
<td rowspan="2" align="char" char=".">2009</td>
<td rowspan="2" align="left">Slovenia</td>
<td rowspan="2" align="char" char=".">87</td>
<td rowspan="2" align="left">pros</td>
<td align="center">63 (47&#x2013;75)</td>
<td rowspan="2" align="center">0.366</td>
<td rowspan="2" align="left">Colorectal cancer</td>
<td align="left">XELIRI</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B81">Skof et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="center">62 (34&#x2013;75)</td>
<td align="left">FOLFIRI</td>
</tr>
<tr>
<td align="left">37</td>
<td align="left">Ardavanis A</td>
<td align="char" char=".">2008</td>
<td align="left">Greece</td>
<td align="char" char=".">34</td>
<td align="left">retro</td>
<td align="center">69.5 (37&#x2013;83)</td>
<td align="center">0.47</td>
<td align="left">Colorectal cancer</td>
<td align="left">CapIRI &#x2b; Bev</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B2">Ardavanis et al. (2008)</xref>
</td>
</tr>
<tr>
<td align="left">38</td>
<td align="left">Kosmas C</td>
<td align="char" char=".">2008</td>
<td align="left">Greece</td>
<td align="char" char=".">644</td>
<td align="left">pros</td>
<td align="center">66 (56&#x2013;70)</td>
<td align="center">NA</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-FU based or Cap based</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B46">Kosmas et al. (2008)</xref>
</td>
</tr>
<tr>
<td align="left">39</td>
<td align="left">Yamamoto D</td>
<td align="char" char=".">2008</td>
<td align="left">Japan</td>
<td align="char" char=".">59</td>
<td align="left">pros</td>
<td align="center">55 (42&#x2013;70)</td>
<td align="center">1</td>
<td align="left">Breast cancer</td>
<td align="left">Cap &#x2b; Tra</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B90">Yamamoto et al. (2008)</xref>
</td>
</tr>
<tr>
<td align="left">40</td>
<td align="left">Machiels JP</td>
<td align="char" char=".">2007</td>
<td align="left">Belgium</td>
<td align="char" char=".">40</td>
<td align="left">pros</td>
<td align="center">61 (34&#x2013;78)</td>
<td align="center">0.33</td>
<td align="left">Rectal cancer</td>
<td align="left">Cap &#x2b; Cet &#x2b; RT</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B57">Machiels et al. (2007)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">41</td>
<td rowspan="2" align="left">Giantonio BJ</td>
<td rowspan="2" align="char" char=".">2007</td>
<td rowspan="2" align="left">United States</td>
<td rowspan="2" align="char" char=".">572</td>
<td rowspan="2" align="left">pros</td>
<td align="center">62 (21&#x2013;85)</td>
<td align="center">0.395</td>
<td rowspan="2" align="left">Colorectal cancer</td>
<td align="left">FOLFOX4 &#x2b;Bev</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B26">Giantonio et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="center">60.8 (25&#x2013;84)</td>
<td align="center">0.392</td>
<td align="left">FOLFOX4</td>
</tr>
<tr>
<td align="left">42</td>
<td align="left">Yilmaz U</td>
<td align="char" char=".">2007</td>
<td align="left">Turkey</td>
<td align="char" char=".">27</td>
<td align="left">pros</td>
<td align="center">54 (19&#x2013;70)</td>
<td align="center">0.444</td>
<td align="left">Gastrointestinal cancer</td>
<td align="left">LV5FU2</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B92">Yilmaz et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">43</td>
<td align="left">Emmanouilides C</td>
<td align="char" char=".">2007</td>
<td align="left">Greece</td>
<td align="char" char=".">53</td>
<td align="left">pros</td>
<td align="center">65 (18&#x2013;78)</td>
<td align="center">0.434</td>
<td align="left">Colorectal cancer</td>
<td align="left">FOLFOX &#x2b; Bev</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B22">Emmanouilides et al. (2007)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">44</td>
<td rowspan="2" align="left">Geyer CE</td>
<td rowspan="2" align="char" char=".">2006</td>
<td rowspan="2" align="left">United States</td>
<td rowspan="2" align="char" char=".">324</td>
<td rowspan="2" align="left">pros</td>
<td align="center">54 (26&#x2013;80)</td>
<td rowspan="2" align="center">1</td>
<td rowspan="2" align="left">Breast cancer</td>
<td align="left">Cap &#x2b; Lap</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B25">Geyer et al. (2006)</xref>
</td>
</tr>
<tr>
<td align="center">51 (28&#x2013;83)</td>
<td align="left">Cape</td>
</tr>
<tr>
<td align="left">45</td>
<td align="left">Mambrini A</td>
<td align="char" char=".">2006</td>
<td align="left">Italy</td>
<td align="char" char=".">211</td>
<td align="left">pros</td>
<td align="center">61 (21&#x2013;79)</td>
<td align="center">NA</td>
<td align="left">Pancreatic cancer</td>
<td align="left">FEC</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B58">Mambrini et al. (2006)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">46</td>
<td rowspan="2" align="left">Koopman M</td>
<td rowspan="2" align="char" char=".">2006</td>
<td rowspan="2" align="left">Netherland</td>
<td rowspan="2" align="char" char=".">393</td>
<td rowspan="2" align="left">pros</td>
<td align="center">64 (27&#x2013;84)</td>
<td align="center">0.373</td>
<td rowspan="2" align="left">Colorectal cancer</td>
<td align="left">Cap</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B45">Koopman et al. (2006)</xref>
</td>
</tr>
<tr>
<td align="center">63 (35&#x2013;79)</td>
<td align="center">0.396</td>
<td align="left">CapIRI</td>
</tr>
<tr>
<td rowspan="5" align="left">47</td>
<td rowspan="5" align="left">Jensen SA</td>
<td rowspan="5" align="char" char=".">2006</td>
<td rowspan="5" align="left">Denmark</td>
<td rowspan="5" align="char" char=".">668</td>
<td rowspan="5" align="left">retro</td>
<td rowspan="5" align="center">NA</td>
<td rowspan="5" align="center">NA</td>
<td rowspan="5" align="left">Colorectal or gastric cancers</td>
<td align="left">Cap</td>
<td rowspan="5" align="left">Fair</td>
<td rowspan="5" align="left">
<xref ref-type="bibr" rid="B37">Jensen and Sorensen, (2006)</xref>
</td>
</tr>
<tr>
<td align="left">Cap/Capatin/Docetaxel</td>
</tr>
<tr>
<td align="left">5-FU</td>
</tr>
<tr>
<td align="left">LV5FU2</td>
</tr>
<tr>
<td align="left">FOLFOX-4</td>
</tr>
<tr>
<td rowspan="2" align="left">48</td>
<td rowspan="2" align="left">Yerushalmi R</td>
<td rowspan="2" align="char" char=".">2006</td>
<td rowspan="2" align="left">Israel</td>
<td rowspan="2" align="char" char=".">89</td>
<td rowspan="2" align="left">retro</td>
<td align="center">66 (25&#x2013;82)</td>
<td align="center">0.418</td>
<td rowspan="2" align="left">Rectal cancer</td>
<td align="left">Cap &#x2b; RT</td>
<td rowspan="2" align="left">Fair</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B91">Yerushalmi et al. (2006)</xref>
</td>
</tr>
<tr>
<td align="center">62 (23&#x2013;81)</td>
<td align="center">0.5</td>
<td align="left">5-FU &#x2b; RT</td>
</tr>
<tr>
<td align="left">49</td>
<td align="left">Giordano KF</td>
<td align="char" char=".">2006</td>
<td align="left">United States</td>
<td align="char" char=".">44</td>
<td align="left">pros</td>
<td align="center">57 (32&#x2013;77)</td>
<td align="center">0.114</td>
<td align="left">Gastric or gastro-esophageal junction adenocarcinoma</td>
<td align="left">TX</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B27">Giordano et al. (2006)</xref>
</td>
</tr>
<tr>
<td align="left">50</td>
<td align="left">Jatoi A</td>
<td align="char" char=".">2006</td>
<td align="left">United States</td>
<td align="char" char=".">46</td>
<td align="left">pros</td>
<td align="center">61 (32&#x2013;80)</td>
<td align="center">0.116</td>
<td align="left">Esophageal or gastro-esophageal junction adenocarcinoma</td>
<td align="left">XELOX</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B35">Jatoi et al. (2006)</xref>
</td>
</tr>
<tr>
<td align="left">51</td>
<td align="left">Baghi M</td>
<td align="char" char=".">2006</td>
<td align="left">Germany</td>
<td align="char" char=".">24</td>
<td align="left">pros</td>
<td align="center">60 (23&#x2013;79)</td>
<td align="center">0.042</td>
<td align="left">Head and neck squamous cell carcinoma</td>
<td align="left">TPF</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B3">Baghi et al. (2006)</xref>
</td>
</tr>
<tr>
<td align="left">562</td>
<td align="left">Meydan N</td>
<td align="char" char=".">2005</td>
<td align="left">Turkey</td>
<td align="char" char=".">231</td>
<td align="left">retro</td>
<td align="center">59 (23&#x2013;87)</td>
<td align="center">0.402</td>
<td align="left">Mixed malignancies</td>
<td align="left">LV5FU2</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B63">Meydan, (2005)</xref>
</td>
</tr>
<tr>
<td align="left">53</td>
<td align="left">Lordick F</td>
<td align="char" char=".">2005</td>
<td align="left">Germany</td>
<td align="char" char=".">48</td>
<td align="left">pros</td>
<td align="center">62 (41&#x2013;75)</td>
<td align="center">0.187</td>
<td align="left">Gastric cancer</td>
<td align="left">FUFOX</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B54">Lordick et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">54</td>
<td align="left">Ng M</td>
<td align="char" char=".">2005</td>
<td align="left">United Kingdom</td>
<td align="char" char=".">153</td>
<td align="left">pros</td>
<td align="center">33&#x2013;81</td>
<td align="center">0.412</td>
<td align="left">Colorectal cancer</td>
<td align="left">CapeOx</td>
<td align="left">Good</td>
<td align="left">
<xref ref-type="bibr" rid="B67">Ng et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">55</td>
<td align="left">Feliu J</td>
<td align="char" char=".">2005</td>
<td align="left">Spain</td>
<td align="char" char=".">51</td>
<td align="left">pros</td>
<td align="center">76 (71&#x2013;89)</td>
<td align="center">0.392</td>
<td align="left">Colorectal cancer</td>
<td align="left">Cap</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B23">Feliu et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">56</td>
<td align="left">Wacker A</td>
<td align="char" char=".">2003</td>
<td align="left">Germany</td>
<td align="char" char=".">102</td>
<td align="left">pros</td>
<td align="center">61.7 (39&#x2013;78)</td>
<td align="center">0.311</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-FU or 5-FU based</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B88">Wacker et al. (2003)</xref>
</td>
</tr>
<tr>
<td align="left">57</td>
<td align="left">Vaishampayan UN</td>
<td align="char" char=".">2002</td>
<td align="left">United States</td>
<td align="char" char=".">32</td>
<td align="left">retro</td>
<td align="center">67.5 (45&#x2013;84)</td>
<td align="center">0.375</td>
<td align="left">Gastrointestinal cancer</td>
<td align="left">Cap &#x2b; RT</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B86">Vaishampayan et al. (2002)</xref>
</td>
</tr>
<tr>
<td align="left">58</td>
<td align="left">Tsavaris N</td>
<td align="char" char=".">2002</td>
<td align="left">Greece</td>
<td align="char" char=".">427</td>
<td align="left">retro</td>
<td align="center">NA</td>
<td align="center">NA</td>
<td align="left">Mixed malignancies</td>
<td align="left">5-Fu based</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B84">Tsavaris et al. (2002)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">59</td>
<td rowspan="3" align="left">Van Cutsem E</td>
<td rowspan="3" align="char" char=".">2002</td>
<td rowspan="3" align="left">Switzerland</td>
<td rowspan="3" align="char" char=".">1,425</td>
<td rowspan="3" align="left">pros</td>
<td align="center">NA</td>
<td rowspan="3" align="center">NA</td>
<td align="left">Colorectal cancer</td>
<td align="left">LV5FU2</td>
<td rowspan="3" align="left">Fair</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B87">Van Cutsem et al. (2002)</xref>
</td>
</tr>
<tr>
<td align="center">NA</td>
<td align="left">Colorectal cancer</td>
<td align="left">Cap</td>
</tr>
<tr>
<td align="center">NA</td>
<td align="left">Breast cancer</td>
<td align="left">Cap</td>
</tr>
<tr>
<td align="left">60</td>
<td align="left">Hartung G</td>
<td align="char" char=".">2001</td>
<td align="left">Germany</td>
<td align="char" char=".">51</td>
<td align="left">pros</td>
<td align="center">60 (24&#x2013;77)</td>
<td align="center">0.25</td>
<td align="left">Colorectal cancer</td>
<td align="left">LV5FU2</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B30">Hartung et al. (2001)</xref>
</td>
</tr>
<tr>
<td align="left">61</td>
<td align="left">Dencausse Y</td>
<td align="char" char=".">2001</td>
<td align="left">Germany</td>
<td align="char" char=".">21</td>
<td align="left">pros</td>
<td align="center">30&#x2013;80</td>
<td align="center">0.333</td>
<td align="left">Rectal cancer</td>
<td align="left">LV5FU2&#x2b;RT</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B17">Dencausse et al. (2001)</xref>
</td>
</tr>
<tr>
<td align="left">62</td>
<td align="left">Peiffert D</td>
<td align="char" char=".">2001</td>
<td align="left">France</td>
<td align="char" char=".">80</td>
<td align="left">pros</td>
<td align="center">&#x2264;75</td>
<td align="center">0.837</td>
<td align="left">Anal cancer</td>
<td align="left">FP &#x2b; RT</td>
<td align="left">Fair</td>
<td align="left">
<xref ref-type="bibr" rid="B72">Peiffert et al. (2001)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">63</td>
<td rowspan="2" align="left">Hoff PM</td>
<td rowspan="2" align="char" char=".">2001</td>
<td rowspan="2" align="left">Multi-country</td>
<td rowspan="2" align="char" char=".">605</td>
<td rowspan="2" align="left">pros</td>
<td align="center">64 (23&#x2013;86)</td>
<td align="center">0.40</td>
<td rowspan="2" align="left">Colorectal cancer</td>
<td align="left">Cap</td>
<td rowspan="2" align="left">Good</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B34">Hoff, (2001)</xref>
</td>
</tr>
<tr>
<td align="center">63 (24&#x2013;87)</td>
<td align="center">0.35</td>
<td align="left">LV5FU2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Notes: a, Mixed malignancies: including two or more tumor types, such as breast cancer, colorectal cancer, gastric cancer, head and neck cancer, and so on; NA: not available; RT: radiotherapy; Cap: Capecitabine; Bev: Bevacizumab; Cet: Cetuximab; Pan: Panitumumab; Tra, Trastuzumab; Lap, Lapatinib.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-2">
<title>The Incidence of 5-Fluorouracil Associated Coronary Artery Disorders</title>
<p>Using a random-effect model, the pooled incidence of all-grade fluoropyrimidine-related coronary disorders among 22,939 cases from 59 studies was 2.75% (95% CI 1.89%&#x2013;3.76%) (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Thirty-three studies reported the incidence of grade 3 or higher fluoropyrimidine-related coronary disorders, involving a total of 14,135 cases, The pooled incidence of grade 3 or higher coronary disorders by meta-analysis, was 1.00% (95% CI 0.62%&#x2013;1.47%) (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Forest plot of the incidence of fluoropyrimidine-related coronary disorders. <bold>(A)</bold> the pooled incidence of all-grade adverse coronary events, by a random-effect model analysis, was 2.75% (95% CI 1.89%&#x2013;3.76%); <bold>(B)</bold> the pooled incidence of grade 3 or higher adverse coronary events, by a random-effect model analysis, was and 1.00% (95% CI 0.62%&#x2013;1.47%).</p>
</caption>
<graphic xlink:href="fphar-13-885699-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Specific Reported Events of Coronary Disorders</title>
<p>Coronary disorders were frequently reported as angina/chest pain, myocardial infarction, myocardial ischemia, and acute coronary syndrome in our included literature. As shown in <xref ref-type="fig" rid="F3">Figure 3</xref>, myocardial ischemia and angina/chest pain were the two most common adverse events, which have a pooled incidence of 1.28% (95% CI 0.42%&#x2013;2.49%) and 1.1% (95% CI 0.54%&#x2013;1.81%), respectively. Myocardial infarction and the acute coronary syndrome were less reported, with a pooled incidence of 0.38% (95% CI 0.16%&#x2013;0.67%) and 0.14% (0&#x2013;0.56%), respectively. Fourteen studies reported the typical ST-T changes on ECG with or without symptomatic coronary toxicities. A random-effect meta-analysis gave a pooled incidence of ST-T changes of 4.77% (95% CI 3.12%&#x2013;7.28%), significantly higher than the incidence of adverse coronary events (2.75%). The changes of cardiac-specific serum enzymes were reported in 10 studies, including troponin, CK-MB, myoglobin, BNP, and copeptin, and the pooled overall incidence was 1.98% (95% CI 0.9%&#x2013;4.36%).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>The pooled incidence of specific reported events of coronary disorders. &#x2a; a pooled incidence of 4.77% (95% CI 3.12%&#x2013;7.28%), containing ST-T changes on ECG with or without symptomatic coronary toxicities.</p>
</caption>
<graphic xlink:href="fphar-13-885699-g003.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Subgroup Analyses</title>
<p>Subgroup analyses were conducted to compare the incidence of all-grade and grade 3 or higher coronary disorders among different study-level moderators, and further identify the factors influencing the occurrence of adverse coronary events. The pooled incidence and 95% CI of coronary events in each subgroup were shown in <xref ref-type="table" rid="T2">Table 2</xref>, as well as the results of statistical comparisons between subgroups. A significant difference was identified among different publication periods (<italic>p</italic> &#x3d; 0.02) for the incidence of all-grade coronary events, but not statistically significant for grade 3 or higher events (<italic>p</italic> &#x3d; 0.65). We did not observe an obvious difference between prospective and retrospective study designs (all-grade: <italic>p</italic> &#x3d; 0.58, grade 3 or higher: <italic>p</italic> &#x3d; 0.21), nor between phase &#x2161; and phase &#x2162; clinical trials (all-grade: <italic>p</italic> &#x3d; 0.24, grade 3 or higher: <italic>p</italic> &#x3d; 0.18). There was also no significant difference between studies with good-quality and fair-quality (<italic>p</italic> &#x3d; 0.43) for all-grade events, however, the good-quality studies had lower pooled incidence than fair-quality studies for the assessment of grade 3 or higher coronary events (<italic>p</italic> &#x3c; 0.01). Notably, the female-only population (with breast cancer) reported lower pooled incidence than general populations, both in the assessment of all-grade (<italic>p</italic> &#x3c; 0.01) and grade 3 or higher (<italic>p</italic> &#x3c; 0.01) coronary disorders.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>The pooled incidence of coronary disorder in each subgroup and the comparison results.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="left">Subgroup</th>
<th colspan="3" align="center">All-grade adverse coronary events</th>
<th colspan="3" align="center">Grade 3 or higher adverse coronary events</th>
</tr>
<tr>
<th align="center">Sample size (<italic>N</italic>)</th>
<th align="center">Incidence (95%CI)</th>
<th align="center">Comparison results</th>
<th align="center">Sample size (<italic>N</italic>)</th>
<th align="center">Incidence (95%CI)</th>
<th align="center">Comparison results</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="7" align="left">Publication period</td>
</tr>
<tr>
<td align="left">&#x2003;2001&#x2013;2005</td>
<td align="char" char=".">1,196</td>
<td align="center">4.27% (2.16%&#x2013;7.06%)</td>
<td rowspan="4" align="center">&#x3c7;<sup>2</sup> &#x3d; 10.15, <italic>p</italic> &#x3d; 0.02&#x2a;</td>
<td align="char" char=".">1,329</td>
<td align="center">0.92% (0.00%&#x2013;3.26%)</td>
<td rowspan="4" align="center">&#x3c7;<sup>2</sup> &#x3d; 1.64, <italic>p</italic> &#x3d; 0.65</td>
</tr>
<tr>
<td align="left">&#x2003;2006&#x2013;2010</td>
<td align="char" char=".">3,190</td>
<td align="center">1.28% (0.65%&#x2013;2.13%)</td>
<td align="char" char=".">1767</td>
<td align="center">1.12% (0.25%&#x2013;2.40%)</td>
</tr>
<tr>
<td align="left">&#x2003;2011&#x2013;2015</td>
<td align="char" char=".">1,635</td>
<td align="center">3.05% (0.93%&#x2013;6.31%)</td>
<td align="char" char=".">810</td>
<td align="center">0.58% (0.00%&#x2013;3.11%)</td>
</tr>
<tr>
<td align="left">&#x2003;2016&#x2013;2022</td>
<td align="char" char=".">16,978</td>
<td align="center">3.37% (1.66%&#x2013;5.65%)</td>
<td align="char" char=".">8,804</td>
<td align="center">0.72% (0.29%&#x2013;1.28%)</td>
</tr>
<tr>
<td colspan="7" align="left">Study design</td>
</tr>
<tr>
<td align="left">&#x2003;Prospective study</td>
<td align="char" char=".">13,950</td>
<td align="center">3.02% (1.88%&#x2013;4.42%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 0.31, <italic>p</italic> &#x3d; 0.58</td>
<td align="char" char=".">11,739</td>
<td align="center">0.67% (0.26%&#x2013;1.20%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 1.55, <italic>p</italic> &#x3d; 0.21</td>
</tr>
<tr>
<td align="left">&#x2003;Retrospective study</td>
<td align="char" char=".">9,049</td>
<td align="center">2.62% (1.98%&#x2013;3.34%)</td>
<td align="char" char=".">971</td>
<td align="center">1.42% (0.30%&#x2013;3.08%)</td>
</tr>
<tr>
<td colspan="7" align="left">Phase for clinical trials</td>
</tr>
<tr>
<td align="left">&#x2003;&#x2161;</td>
<td align="char" char=".">938</td>
<td align="center">1.93% (1.14%&#x2013;2.92%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 1.41, <italic>p</italic> &#x3d; 0.24</td>
<td align="char" char=".">711</td>
<td align="center">0.15% (0.38%&#x2013;2.62%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 1.76, <italic>p</italic> &#x3d; 0.18</td>
</tr>
<tr>
<td align="left">&#x2003;&#x2162;</td>
<td align="char" char=".">7,617</td>
<td align="center">1.18% (0.49%&#x2013;2.16%)</td>
<td align="char" char=".">8,576</td>
<td align="center">0.69% (0.29%&#x2013;1.09%)</td>
</tr>
<tr>
<td colspan="7" align="left">Study quality</td>
</tr>
<tr>
<td align="left">&#x2003;Good</td>
<td align="char" char=".">18,385</td>
<td align="center">2.12% (1.08%&#x2013;3.48%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 1.67, <italic>p</italic> &#x3d; 0.43</td>
<td align="char" char=".">10,970</td>
<td align="center">0.58% (0.20%&#x2013;1.10%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 9.32, <italic>p</italic>&#xff1c;0.01&#x2a;</td>
</tr>
<tr>
<td align="left">&#x2003;Fair</td>
<td align="char" char=".">4,162</td>
<td align="center">3.35% (2.03%&#x2013;4.98%)</td>
<td align="char" char=".">1740</td>
<td align="center">1.51% (0.70%&#x2013;2.54%)</td>
</tr>
<tr>
<td colspan="7" align="left">Age</td>
</tr>
<tr>
<td align="left">&#x2003;No limitation</td>
<td align="char" char=".">22,797</td>
<td align="center">2.75% (1.87%&#x2013;3.79%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 0.04, <italic>p</italic> &#x3d; 0.84</td>
<td align="char" char=".">12,639</td>
<td align="center">0.78% (0.35%&#x2013;1.33%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 1.07, <italic>p</italic> &#x3d; 0.30</td>
</tr>
<tr>
<td align="left">&#x2003;Old</td>
<td align="char" char=".">202</td>
<td align="center">2.17% (0.00%&#x2013;10.00%)</td>
<td align="char" char=".">71</td>
<td align="center">0.00% (0.00%&#x2013;5.06%)</td>
</tr>
<tr>
<td colspan="7" align="left">Gender</td>
</tr>
<tr>
<td align="left">&#x2003;All</td>
<td align="char" char=".">20,556</td>
<td align="center">3.48% (2.44%&#x2013;4.70%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 18.59, <italic>p</italic> &#x3c; 0.01&#x2a;</td>
<td align="char" char=".">11,204</td>
<td align="center">1.09% (0.53%&#x2013;1.78%)</td>
<td rowspan="2" align="center">&#x3c7;<sup>2</sup> &#x3d; 15.75, <italic>p</italic> &#x3c; 0.01&#x2a;</td>
</tr>
<tr>
<td align="left">&#x2003;Female-only</td>
<td align="char" char=".">2,355</td>
<td align="center">0.61% (0.15%&#x2013;1.37%)</td>
<td align="char" char=".">1,418</td>
<td align="center">0.09% (0.00%&#x2013;0.43%)</td>
</tr>
<tr>
<td colspan="7" align="left">Tumor type</td>
</tr>
<tr>
<td align="left">&#x2003;Esophagus cancer</td>
<td align="char" char=".">244</td>
<td align="center">6.32% (3.62%&#x2013;9.71%)</td>
<td rowspan="7" align="center">&#x3c7;<sup>2</sup> &#x3d; 47.59, <italic>p</italic>&#xff1c;0.01&#x2a;</td>
<td align="char" char=".">290</td>
<td align="center">3.51% (1.51%&#x2013;6.14%)</td>
<td rowspan="7" align="center">&#x3c7;<sup>2</sup> &#x3d; 34.41, <italic>p</italic>&#xff1c;0.01&#x2a;</td>
</tr>
<tr>
<td align="left">&#x2003;Colorectal cancer</td>
<td align="char" char=".">12,553</td>
<td align="center">2.69% (1.57%&#x2013;4.09%)</td>
<td align="char" char=".">10,403</td>
<td align="center">0.94% (0.39%&#x2013;1.67%)</td>
</tr>
<tr>
<td align="left">&#x2003;Gastric cancer</td>
<td align="char" char=".">177</td>
<td align="center">2.26% (0.59%&#x2013;4.96%)</td>
<td align="char" char=".">177</td>
<td align="center">2.13% (0.31%&#x2013;5.05%)</td>
</tr>
<tr>
<td align="left">&#x2003;Pancreatic cancer</td>
<td align="char" char=".">227</td>
<td align="center">1.64% (0.00%&#x2013;6.13%)</td>
<td align="char" char=".">16</td>
<td align="center">6.25% (0.16%&#x2013;30.23%)</td>
</tr>
<tr>
<td align="left">&#x2003;Breast cancer</td>
<td align="char" char=".">2,443</td>
<td align="center">0.50% (0.11%&#x2013;1.16%)</td>
<td align="char" char=".">1,506</td>
<td align="center">0.01% (0.00%&#x2013;0.27%)</td>
</tr>
<tr>
<td align="left">&#x2003;Biliary tract cancer</td>
<td align="char" char=".">223</td>
<td align="center">0.45% (0.01%&#x2013;2.47%)</td>
<td align="char" char=".">223</td>
<td align="center">0.45% (0.01%&#x2013;2.47%)</td>
</tr>
<tr>
<td align="left">&#x2003;Others<sup>a</sup>
</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td colspan="7" align="left">Treatment type</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;Adjuvant</td>
<td align="char" char=".">3,703</td>
<td align="center">1.36% (0.16%&#x2013;3.36%)</td>
<td rowspan="3" align="center">&#x3c7;<sup>2</sup> &#x3d; 2.01, <italic>p</italic> &#x3d; 0.37</td>
<td align="char" char=".">3,366</td>
<td align="center">0.94% (0.32%&#x2013;1.88%)</td>
<td rowspan="3" align="center">&#x3c7;<sup>2</sup> &#x3d; 3.84, <italic>p</italic> &#x3d; 0.15</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;Neoadjuvant</td>
<td align="char" char=".">549</td>
<td align="center">2.86% (1.50%&#x2013;4.56%)</td>
<td align="char" char=".">380</td>
<td align="center">2.65% (1.16%&#x2013;4.71%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;For advanced/metastasis/relapse disease</td>
<td align="char" char=".">925</td>
<td align="center">1.70% (0.72%&#x2013;2.97%)</td>
<td align="char" char=".">933</td>
<td align="center">1.10% (0.27%&#x2013;2.48%)</td>
</tr>
<tr>
<td colspan="7" align="left">Regimen</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;5-FU monotherapy</td>
<td align="char" char=".">484</td>
<td align="center">3.31% (1.46%&#x2013;5.87%)</td>
<td rowspan="10" align="center">&#x3c7;<sup>2</sup> &#x3d; 28.65, <italic>p</italic> &#x3c; 0.01&#x2a;</td>
<td align="char" char=".">1,380</td>
<td align="center">0.92% (0.00%&#x2013;3.04%)</td>
<td rowspan="10" align="center">&#x3c7;<sup>2</sup> &#x3d; 15.79, <italic>p</italic> &#x3d; 0.07</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;Capecitabine monotherapy</td>
<td align="char" char=".">2,627</td>
<td align="center">1.21% (0.34%&#x2013;2.59%)</td>
<td align="char" char=".">3,059</td>
<td align="center">0.75% (0.03%&#x2013;1.36%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;5-FU combined chemotherapy</td>
<td align="char" char=".">2,993</td>
<td align="center">4.31% (2.05%&#x2013;7.35%)</td>
<td align="char" char=".">706</td>
<td align="center">1.2% (0.00%&#x2013;4.31%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;Capecitabine combined chemotherapy</td>
<td align="char" char=".">3,956</td>
<td align="center">2.69% (1.09%&#x2013;4.98%)</td>
<td align="char" char=".">1711</td>
<td align="center">0.69% (0.00%&#x2013;2.14%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;5-FU based/targeted therapy</td>
<td align="char" char=".">336</td>
<td align="center">1.46% (0.46%&#x2013;3.02%)</td>
<td align="char" char=".">623</td>
<td align="center">0.83% (0.14%&#x2013;1.87%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;Capecitabine based/targeted therapy</td>
<td align="char" char=".">3,177</td>
<td align="center">2.85% (1.75%&#x2013;4.20%)</td>
<td align="char" char=".">2,483</td>
<td align="center">1.22% (0.46%&#x2013;2.24%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;5-FU based/radio</td>
<td align="char" char=".">181</td>
<td align="center">5.10% (1.58%&#x2013;10.48%)</td>
<td align="char" char=".">21</td>
<td align="center">4.76% (0.12%&#x2013;23.82%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;Capecitabine based/radio</td>
<td align="char" char=".">75</td>
<td align="center">2.65% (0.25%&#x2013;7.47%)</td>
<td align="char" char=".">32</td>
<td align="center">3.12% (0.08%&#x2013;16.22%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;S-1</td>
<td align="char" char=".">71</td>
<td align="center">0.00% (0.00%&#x2013;5.06%)</td>
<td align="char" char=".">71</td>
<td align="center">0.00% (0.00%&#x2013;5.06%)</td>
</tr>
<tr>
<td align="left">&#xa0;&#xa0;TAS 102</td>
<td align="char" char=".">534</td>
<td align="center">0.56% (0.12%&#x2013;1.63%)</td>
<td align="char" char=".">534</td>
<td align="center">0.19% (0.00%&#x2013;1.04%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Notes: &#x2a;<italic>p</italic> &#x3c; 0.05; a, &#x201c;others&#x201d; including liver cancer, gastrointestinal cancer, and head and neck cancer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The pooled incidence of coronary disorders for all-grade or grade 3 or higher varied between tumor types (all-grade: <italic>p</italic> &#x3c; 0.01, grade 3 or higher: <italic>p</italic> &#x3c; 0.01). Fluoropyrimidine-related coronary disorders were most frequently in the treatment of esophageal cancer, with the all-grade incidence of 6.32% (95% CI 3.62%&#x2013;9.71%). Fluoropyrimidines in the treatment of breast cancer, however, occupied the relatively lower coronary complications (all-grade: 0.50%, 95% CI 0.11%&#x2013;1.16%) than colorectal cancer (all-grade: 2.69%, 95% CI 1.57%&#x2013;4.09%) and esophagus cancer.</p>
<p>The effect of treatment parameters on the incidence of coronary events was also analyzed. As a result, the administrations of fluoropyrimidine as neoadjuvant chemotherapy, adjuvant chemotherapy, or palliative treatment for advanced/metastasis/relapse disease did not significantly affect the occurrence of coronary events (all-grade: <italic>p</italic> &#x3d; 0.37; grade 3 or higher: <italic>p</italic> &#x3d; 0.15). However, the treatment regimen is closely related to the occurrence of coronary disorders (all-grade: <italic>p</italic> &#x3c; 0.01; grade 3 or higher: <italic>p</italic> &#x3d; 0.07). Coronary disorder induced by 5-FU is more frequent than that induced by capecitabine, both for all-grade (3.31% vs. 1.21%) and grade 3 or higher (0.92% vs. 0.75%). The 5-FU or capecitabine combined chemotherapy had a higher incidence of coronary events than 5-FU or capecitabine monotherapy (5-FU: 4.31% vs. 3.31%; capecitabine: 2.69% vs. 1.21%). The addition of targeted therapy drugs (e.g., bevacizumab, cetuximab, and trastuzumab) to capecitabine increased the risk of coronary disorder (all-grade; 2.85% vs. 1.21%; grade 3 or higher: 1.22% vs. 0.75%). Similarly, the addition of radiotherapy resulted in a significant increase in coronary toxicity, both for 5-FU (all-grade: 5.1% vs. 3.3%, grade 3 or higher: 4.76% vs. 0.92%) and capecitabine (all-grade: 2.65% vs. 1.21%, grade 3 or higher: 3.12% vs. 0.75%). Novel fluoropyrimidines, S-1 and Tas 102, demonstrated lower coronary toxicity (S-1: 0; Tas102: 0.56%), however, such data were derived from a limited number of studies.</p>
</sec>
<sec id="s3-5">
<title>Sensitive Analyses and Publication Bias</title>
<p>Sensitivity analyses were performed for the main outcome measures, all-grade and grade 3 or higher incidence of coronary disorders. In the all-grade and grade 3 or higher analyses, the variation of the pooled results after removing studies one by one was 2.64%&#x2013;2.86% and 0.92%&#x2013;1.07%, respectively (<xref ref-type="fig" rid="F4">Figure 4</xref>), indicating that the conclusions of this meta-analysis were stable and reliable. The funnel plots and Egger tests did not show existing significant publication bias in the evaluation of all-grade and grade 3 or higher coronary disorder in this meta-analysis (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>The results of sensitive analysis. <bold>(A)</bold> the sensitive analysis of the incidence of all-grade coronary disorders indicated a variation between 2.64% and 2.86%; <bold>(B)</bold> the sensitive analysis of the incidence of grade 3 or higher coronary disorders indicated a variation between 0.92% and 1.07%.</p>
</caption>
<graphic xlink:href="fphar-13-885699-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Funnel plot and Egger test evaluating the publication bias of studies. The <italic>p</italic>-values of Egger test for all-grade and grade 3 or higher coronary disorder were 0.92 and 0.91, respectively, suggesting no significant publication bias.</p>
</caption>
<graphic xlink:href="fphar-13-885699-g005.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Fluoropyrimidine, as a well-known class of pyrimidine antimetabolites, has been used in cancer treatment for more than half a century. Although numerous therapeutic strategies have been introduced in recent years, such as targeted therapy (<xref ref-type="bibr" rid="B6">Bedard et al., 2020</xref>), antiangiogenic therapy, and immunotherapy (<xref ref-type="bibr" rid="B32">Hegde and Chen, 2020</xref>), fluoropyrimidines are still one of the most effective and frequently used agents in the treatment of colorectal cancer, breast cancer, gastric cancer, and head and neck cancers, whether for neoadjuvant, adjuvant, advanced or maintenance therapy. Cardiotoxicity, especially coronary disorders caused by 5-FU and capecitabine remains a critical issue in cancer therapy that threatens patient survival and leads to the discontinuation of the medication. Unfortunately, there is no solid evidence worldwide about the incidence of fluoropyrimidine-related coronary disorders and the risk factors affecting its occurrence (<xref ref-type="bibr" rid="B15">Deac et al., 2020</xref>; <xref ref-type="bibr" rid="B53">Li et al., 2021</xref>). In this study, we systematically evaluated the incidence and profile of coronary disorder associated with fluoropyrimidines administration. To our best knowledge, this is the first comprehensive systematic review and meta-analysis on this topic.</p>
<p>The mechanism of fluoropyrimidine-induced cardiotoxicity has not yet been fully elucidated. Although several theories have been proposed, including vasoconstriction, endothelial injury, direct myocardial toxicity, and so on, the most predominant and important clinicopathological change was the disorder of coronary artery (<xref ref-type="bibr" rid="B18">Depetris et al., 2018</xref>; <xref ref-type="bibr" rid="B65">Mohammed et al., 2018</xref>; <xref ref-type="bibr" rid="B10">Chong and Ghosh, 2019</xref>). The coronary disorders defined in this study mainly refers to reversible cardiac ischemia caused by coronary vasospasm, and coronary atherosclerosis due to fluorouracil-induced coagulation problems was also included. There are several reported presentations of fluoropyrimidine-related coronary disorders, including atypical chest pain to typical angina, ACS, myocardial ischemia, and myocardial infarction. According to our results, myocardial ischemia (1.28%) and angina/chest pain (1.1%) are the most frequently reported. In fact, ischemia and angina/chest pain are not two independent adverse events. Chest pain with or without typical angina is often the primary clinical manifestation of acute cardiac ischemia or ACS, both of which are outcomes of coronary disorders. Thus, in this analysis, we focused on the overall coronary disorders consisting of angina/chest pain, myocardial ischemia and infarction, and ACS, rather than one of them.</p>
<p>Our results generated reliable data on the overall incidence of fluoropyrimidine-related coronary disorder of 2.7%, which revised the previous over-or under-estimation of 0&#x2013;35%. The incidence of grade 3 or higher fluoropyrimidine reached 1%, accounting for 37% of the overall incidence, indicating that coronary disorder is one of the high-risk complications, which deserves special attention. The pooled results in our study were close to the data reported by <xref ref-type="bibr" rid="B93">Zafar et al. (2021)</xref>, in which coronary disorders occurred in 2.16% of 4,019 patients treated with 5-FU. It should be noted that 14 of the 63 included studies observed ECG changes during fluoropyrimidine administration, with a pooled incidence of ST-T changes of 4.77%, remarkably exceeding the incidence of adverse coronary events (2.16%). Such inconsistency may be derived from the presence of asymptomatic ischemic ECG changes in some populations (<xref ref-type="bibr" rid="B56">Lounsbury et al., 2017</xref>). Therefore, continuous ECG monitoring should be recommended during fluoropyrimidine use, as early ST-T changes often indicate an impending adverse coronary event.</p>
<p>The results of our subgroup analysis showed a lower incidence of the coronary disorder in the female-only population, a phenomenon that has also been observed in other studies (<xref ref-type="bibr" rid="B73">Peng et al., 2018</xref>). <xref ref-type="bibr" rid="B16">Delaloge et al. (2020)</xref> reported 5 (0.8%) of 628 breast cancer patients treated with capecitabine developed coronary disorders in a phase &#x2162; clinical trial. A similar low incidence (0.5%, 2/397) was also reported by <xref ref-type="bibr" rid="B94">Zhang et al. (2017)</xref> in 2017. Such gender differences may be associated with the protective effect of female hormones on the heart (<xref ref-type="bibr" rid="B48">Kurokawa et al., 2009</xref>; <xref ref-type="bibr" rid="B28">Gowd and Thompson, 2012</xref>; <xref ref-type="bibr" rid="B12">Costa et al., 2021</xref>). However, in this pooled analysis, the female-only population were breast cancer patients with capecitabine administration. We believed that the characteristics in tumor type and medication should be mainly accounted for the lower coronary toxicity in the female-only population. In addition, a significant difference on the incidence of all-grade adverse coronary events was also observed among different publication periods. This discrepancy could be partly related to the way of drug administration, increased concomitant targeted therapy, and increased attention to cardiotoxicity.</p>
<p>We had observed a significant difference in fluoropyrimidine-related coronary disorders among different tumor types. However, these differences, to a great extent, should be attributed to the variability in treatment regimens among tumors. Capecitabine is an oral prodrug of 5-FU designed to be converted selectively in tumors. It is rapidly absorbed from the gut as an unchanged drug and then converted to the active form of 5-FU by carboxylesterase and thymidine phosphorylase (<xref ref-type="bibr" rid="B69">O&#x2019;Connell et al., 2014</xref>). Therefore, the effect of capecitabine on the coronary is indirect, and our results seem to show that the incidence of capecitabine-caused coronary disorders is significantly lower than that of intravenous 5-FU. However, due to the lack of evidence of direct comparison between 5-FU and capecitabine, such a conclusion needs further confirmation. The coronary toxicity was distinctly varied from formulations or administration protocols of 5-FU or capecitabine. Combination therapy significantly increases coronary toxicity, whether combined with other chemotherapeutics or targeted therapy. The increased incidence of the coronary disorder in combination therapy may result from additive and synergistic toxic effects of different agents on the heart. As we know, anti-angiogenic targeted drugs (e.g., bevacizumab) also had adverse effects on the cardiovascular system (<xref ref-type="bibr" rid="B21">Economopoulou et al., 2015</xref>). Therefore, when combination regimens containing these agents were considered, more attention should be paid to the occurrence of coronary adverse events. On the other hand, radiotherapy covering or adjacent to the heart also significantly increases coronary toxicity of fluoropyrimidines. As in our meta-analysis, patients with esophageal cancer who received 5-FU combined with radiotherapy had the highest incidence of coronary disorder at 6.32%. Some studies further showed that radiotherapy increases not only short-term cardiotoxicity, but also long-term cardiotoxicity, such as pericarditis and pericardial effusion (<xref ref-type="bibr" rid="B79">Saunders and Anwar, 2019</xref>). Other fluoropyrimidine drugs, such as S-1 and TAS102, have shown a lower incidence of coronary disorders in our study and may be a safer option for patients. However, due to the limited number of cases included in the TAS102 and S1 analyses, more evidence is needed.</p>
<p>Admittedly, there were some limitations in this meta-analysis. First, heterogeneity was observed among the included studies. Although we have performed subgroup analyses and adopted a random-effect model to minimize the effects of the heterogeneity, its influence on the stability of the results cannot be eliminated. Second, it is difficult to clearly define and distinguish &#x201c;coronary disorder,&#x201d; although in this study we included various manifestations such as angina, chest pain, myocardial infarction, myocardial ischemia, and ACS. Not all included studies have undertaken a comprehensive and targeted examination to identify these conditions, so the result may be an inevitable underestimation of the incidence. Furthermore, it is difficult to determine whether the referred coronary disorder was related to fluoropyrimidine-containing treatment. Although we only included studies that clearly indicated such a correlation, there is still a possibility that patients with spontaneous coronary disorder could be counted in the original study. Finally, several previous studies have reported the effects of age, race, smoking, history of heart disease, and other factors on fluoropyrimidine-related coronary toxicity. However, limited by the characteristics of the included studies in this meta-analysis, we did not have enough data to further analyze all possible moderators. Owing to the above limitations, the findings of this meta-analysis should be interpreted with carefully, and subsequent large-sample clinical studies are necessary.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>In conclusion, this meta-analysis, which used a single-rate pooled analysis model, has defined the incidence of coronary disorders induced by fluoropyrimidine-based treatment, and depicted its epidemiological profiles. The occurrence of fluoropyrimidine-related coronary disorders is not a rare condition during fluoropyrimidine administration, which needs to be highly concerned. It varies among tumor types, and different treatment regimens may be associated with different incidence of adverse coronary events. This comprehensive overview of fluoropyrimidine-related coronary disorders can provide a reference for clinical practice in cancer management.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>YL: literature retrieval, data extraction, literature quality evaluation, and article writing; SD: literature retrieval, data extraction, literature quality evaluation; QD, WP, and QL: data verification; HJ and XW: statistical analysis; H-MZ: study design and quality supervision.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.885699/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2022.885699/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdel-Rahman</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>5-Fluorouracil-related Cardiotoxicity; Findings from Five Randomized Studies of 5-Fluorouracil-Based Regimens in Metastatic Colorectal Cancer</article-title>. <source>Clin. Colorectal Cancer</source> <volume>18</volume> (<issue>1</issue>), <fpage>58</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.clcc.2018.10.006</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ardavanis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kountourakis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mantzaris</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Malliou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Doufexis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sykoutri</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Bevacizumab Added to the Irinotecan and Capecitabine Combination for Advanced Colorectal Cancer: A Well-Tolerated, Active and Convenient Regimen</article-title>. <source>Anticancer Res.</source> <volume>28</volume> (<issue>5B</issue>), <fpage>3087</fpage>&#x2013;<lpage>3092</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2008.26.15_suppl.15085</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baghi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hambek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wagenblast</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>May</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>GstoettnerGstoettner</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Knecht</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>A Phase II Trial of Docetaxel, Cisplatin and 5-fluorouracil in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)</article-title>. <source>Anticancer Res.</source> <volume>26</volume> (<issue>1B</issue>), <fpage>585</fpage>&#x2013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.07.446</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldeo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baldeo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mody</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Seegobin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rollini</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>A Case of 5-Fluorouracil-Induced Coronary Artery Vasovasospasm in Rectal Adenocarcinoma</article-title>. <source>J. Am. Coll. Cardiol.</source> <volume>71S</volume> (<issue>11</issue>), <fpage>2324</fpage>. <pub-id pub-id-type="doi">10.1016/S0735-1097(18)32865-1</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baur</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>St&#xe4;ttner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schratter-Sehn</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sellner</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Chemoradiotherapy with 5-fluorouracil/leucovorin, Surgery and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer</article-title>. <source>Oncol. Lett.</source> <volume>1</volume> (<issue>1</issue>), <fpage>189</fpage>&#x2013;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.3892/ol_00000035</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedard</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Davids</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>L. L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Small Molecules, Big Impact: 20 Years of Targeted Therapy in Oncology</article-title>. <source>Lancet</source> <volume>395</volume> (<issue>10229</issue>), <fpage>1078</fpage>&#x2013;<lpage>1088</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30164-1</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben-Yakov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mattu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Dubbs</surname>
<given-names>S. B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Prinzmetal Angina (Coronary Vasospasm) Associated with 5-fluorouracil Chemotherapy</article-title>. <source>Am. J. Emerg. Med.</source> <volume>35</volume> (<issue>e37</issue>), <fpage>1038</fpage>&#x2013;<lpage>e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajem.2017.02.046</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakravarthy</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Meropol</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>L. I.</given-names>
</name>
<name>
<surname>Sloan</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)</article-title>. <source>Oncologist</source> <volume>25</volume> (<issue>5</issue>), <fpage>e798</fpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2019-0437</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>E. Y.</given-names>
</name>
<name>
<surname>Blanke</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Benson</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Dragovich</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lenz</surname>
<given-names>H. J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A Phase II Study of Celecoxib with Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Previously Untreated Advanced or Metastatic Colorectal Cancer</article-title>. <source>Am. J. Clin. Oncol.</source> <volume>41</volume> (<issue>12</issue>), <fpage>1193</fpage>&#x2013;<lpage>1198</lpage>. <pub-id pub-id-type="doi">10.1097/COC.0000000000000465</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions</article-title>. <source>Interv. Cardiol.</source> <volume>14</volume> (<issue>2</issue>), <fpage>89</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.15420/icr.2019.12</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chua</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Barbachano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Oates</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wotherspoon</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Neoadjuvant Capecitabine and Oxaliplatin before Chemoradiotherapy and Total Mesorectal Excision in MRI-Defined Poor-Risk Rectal Cancer: a Phase 2 Trial</article-title>. <source>Lancet Oncol.</source> <volume>11</volume> (<issue>3</issue>), <fpage>241</fpage>&#x2013;<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70381-X</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saguner</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Gasperetti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Akdis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brunckhorst</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duru</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Link between Sex Hormones and Susceptibility to Cardiac Arrhythmias: From Molecular Basis to Clinical Implications</article-title>. <source>Front. Cardiovasc. Med.</source> <volume>8</volume>, <fpage>644279</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2021.644279</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curigliano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cardinale</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dent</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Criscitiello</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Aseyev</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lenihan</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management</article-title>. <source>CA Cancer J. Clin.</source> <volume>66</volume> (<issue>4</issue>), <fpage>309</fpage>&#x2013;<lpage>325</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21341</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>William</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>5-Fluorouracil-induced Acute Coronary Syndrome</article-title>. <source>Med. J. Aust.</source> <volume>211</volume> (<issue>6</issue>), <fpage>255</fpage>&#x2013;<lpage>e1</lpage>. <pub-id pub-id-type="doi">10.5694/mja2.50317</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deac</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Burz</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Bocsan</surname>
<given-names>I. C.</given-names>
</name>
<name>
<surname>Buzoianu</surname>
<given-names>A. D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Fluoropyrimidine-induced Cardiotoxicity</article-title>. <source>World J. Clin. Oncol.</source> <volume>11</volume> (<issue>12</issue>), <fpage>1008</fpage>&#x2013;<lpage>1017</lpage>. <pub-id pub-id-type="doi">10.5306/wjco.v11.i12.1008</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delaloge</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Piccart</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rutgers</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Liti&#xe8;re</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van &#x27;t Veer</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>van den Berkmortel</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Standard Anthracycline Based versus Docetaxel-Capecitabine in Early High Clinical And/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial</article-title>. <source>J. Clin. Oncol.</source> <volume>38</volume> (<issue>11</issue>), <fpage>1186</fpage>&#x2013;<lpage>1197</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.19.01371</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dencausse</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dietzler</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Edler</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bambach</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Adjuvant Radio-Chemotherapy in Stage II-III Rectal Cancer with 24-hour Infusion of High-Dose 5-fluorouracil and Folinic Acid: Evaluation of Feasibility</article-title>. <source>Onkologie</source> <volume>24</volume> (<issue>5</issue>), <fpage>476</fpage>&#x2013;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1159/000055129</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Depetris</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bonzano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cagnazzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Filippi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aglietta</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Fluoropyrimidine-induced Cardiotoxicity</article-title>. <source>Crit. Rev. Oncol. Hematol.</source> <volume>124</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2018.02.002</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyhl-Polk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vistisen</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Sillesen</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Serup-Hansen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Faber</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study</article-title>. <source>Oncologist</source> <volume>26</volume> (<issue>3</issue>), <fpage>E403</fpage>&#x2013;<lpage>E413</lpage>. <pub-id pub-id-type="doi">10.1002/onco.13536</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyhl-Polk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vaage-Nilsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vistisen</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Lund</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>K&#xfc;mler</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>Incidence and Risk Markers of 5-fluorouracil and Capecitabine Cardiotoxicity in Patients with Colorectal Cancer</article-title>. <source>Acta Oncol.</source> <volume>59</volume> (<issue>4</issue>), <fpage>475</fpage>&#x2013;<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1080/0284186X.2019.1711164</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Economopoulou</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kotsakis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kapiris</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kentepozidis</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Cancer Therapy and Cardiovascular Risk: Focus on Bevacizumab</article-title>. <source>Cancer Manag. Res.</source> <volume>7</volume>, <fpage>133</fpage>&#x2013;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.2147/CMAR.S77400</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emmanouilides</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sfakiotaki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Androulakis</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kalbakis</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Christophylakis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kalykaki</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Front-line Bevacizumab in Combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in Patients with Metastatic Colorectal Cancer: a Multicenter Phase II Study</article-title>. <source>BMC Cancer</source> <volume>7</volume> (<issue>91</issue>), <fpage>91</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-7-91</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feliu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Escudero</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Llosa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bola&#xf1;os</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vicent</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Yubero</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Capecitabine as First-Line Treatment for Patients Older Than 70 Years with Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study</article-title>. <source>J. Clin. Oncol.</source> <volume>23</volume> (<issue>13</issue>), <fpage>3104</fpage>&#x2013;<lpage>3111</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2005.06.035</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tatsch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sides</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Willis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Berbarie</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>5-fluorouracil Induced Coronary Vasospasm and Non-ischemic Cardiomyopathy Presenting in the Same Patient</article-title>. <source>J. Am. Coll. Cardiol.</source> <volume>73</volume> (<issue>9</issue>), <fpage>2477</fpage>. <pub-id pub-id-type="doi">10.1016/S0735-1097(19)33083-9</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geyer</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Forster</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lindquist</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Romieu</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Pienkowski</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer</article-title>. <source>N. Engl. J. Med.</source> <volume>355</volume> (<issue>26</issue>), <fpage>2733</fpage>&#x2013;<lpage>2743</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa064320</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giantonio</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Catalano</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Meropol</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>O&#x27;Dwyer</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>E. P.</given-names>
</name>
<name>
<surname>Alberts</surname>
<given-names>S. R.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Bevacizumab in Combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200</article-title>. <source>J. Clin. Oncol.</source> <volume>25</volume> (<issue>12</issue>), <fpage>1539</fpage>&#x2013;<lpage>1544</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2006.09.6305</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giordano</surname>
<given-names>K. F.</given-names>
</name>
<name>
<surname>Jatoi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stella</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tschetter</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Alberts</surname>
<given-names>S. R.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Docetaxel and Capecitabine in Patients with Metastatic Adenocarcinoma of the Stomach and Gastroesophageal junction: a Phase II Study from the North Central Cancer Treatment Group</article-title>. <source>Ann. Oncol.</source> <volume>17</volume> (<issue>4</issue>), <fpage>652</fpage>&#x2013;<lpage>656</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdl005</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gowd</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P. D.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Effect of Female Sex on Cardiac Arrhythmias</article-title>. <source>Cardiol. Rev.</source> <volume>20</volume> (<issue>6</issue>), <fpage>297</fpage>&#x2013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1097/CRD.0b013e318259294b</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grierson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Teague</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suresh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Phase Ib/II Study Combining Tosedostat with Capecitabine in Patients with Advanced Pancreatic Adenocarcinoma</article-title>. <source>J. Gastrointest. Oncol.</source> <volume>11</volume> (<issue>1</issue>), <fpage>61</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.21037/jgo.2019.11.06</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartung</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hofheinz</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Wein</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rost</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fritze</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Phase II Study of a Weekly 24-hour Infusion with 5-fluorouracil and Simultaneous Sodium-Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer</article-title>. <source>ONKOLOGIE</source> <volume>24</volume> (<issue>5</issue>), <fpage>457</fpage>&#x2013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1159/000055126</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Isohashi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tsujii</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fujinaga</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The Heart&#x27;s Exposure to Radiation Increases the Risk of Cardiac Toxicity after Chemoradiotherapy for Superficial Esophageal Cancer: a Retrospective Cohort Study</article-title>. <source>BMC Cancer</source> <volume>19</volume> (<issue>1</issue>), <fpage>195</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-019-5421-y</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegde</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Top 10 Challenges in Cancer Immunotherapy</article-title>. <source>Immunity</source> <volume>52</volume> (<issue>1</issue>), <fpage>17</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.12.011</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoff</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Ansari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Batist</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kocha</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kuperminc</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>20012001</year>). <article-title>Comparison of Oral Capecitabine versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients with Metastatic Colorectal Cancer: Results of a Randomized Phase III Study</article-title>. <source>Jco</source> <volume>19</volume> (<issue>8</issue>), <fpage>2282</fpage>&#x2013;<lpage>2292</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2001.19.8.2282</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jatoi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>N. R.</given-names>
</name>
<name>
<surname>Nikcevich</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Alberts</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Knost</surname>
<given-names>J. A.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Oxaliplatin and Capecitabine in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal junction and Gastric Cardia: a Phase II Study from the North Central Cancer Treatment Group</article-title>. <source>Ann. Oncol.</source> <volume>17</volume> (<issue>1</issue>), <fpage>29</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdj063</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jensen</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Hasbak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>S&#xf8;rensen</surname>
<given-names>J. B.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Fluorouracil Induces Myocardial Ischemia with Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but without Dysfunction of Left Ventricle</article-title>. <source>J. Clin. Oncol.</source> <volume>28</volume> (<issue>36</issue>), <fpage>5280</fpage>&#x2013;<lpage>5286</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2009.27.3953</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jensen</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>S&#xf8;rensen</surname>
<given-names>J. B.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Risk Factors and Prevention of Cardiotoxicity Induced by 5-fluorouracil or Capecitabine</article-title>. <source>Cancer Chemother. Pharmacol.</source> <volume>58</volume> (<issue>4</issue>), <fpage>487</fpage>&#x2013;<lpage>493</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-005-0178-1</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Incidence of and Risk Factors for Cardiotoxicity after Fluorouracil-Based Chemotherapy in Locally Advanced or Metastatic Gastric Cancer Patients</article-title>. <source>Cancer Chemother. Pharmacol.</source> <volume>84</volume> (<issue>3</issue>), <fpage>599</fpage>&#x2013;<lpage>607</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-019-03888-1</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joensuu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bono</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kataja</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Alanko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kokko</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Asola</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Fluorouracil, Epirubicin, and Cyclophosphamide with Either Docetaxel or Vinorelbine, with or without Trastuzumab, as Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial</article-title>. <source>J. Clin. Oncol.</source> <volume>27</volume> (<issue>34</issue>), <fpage>5685</fpage>&#x2013;<lpage>5692</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2008.21.4577</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanduri</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>More</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Godishala</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Asnani</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Fluoropyrimidine-Associated Cardiotoxicity</article-title>. <source>Cardiol. Clin.</source> <volume>37</volume> (<issue>4</issue>), <fpage>399</fpage>&#x2013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccl.2019.07.004</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karakulak</surname>
<given-names>U. N.</given-names>
</name>
<name>
<surname>Alada&#x11f;</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Maharjan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>&#xd6;v&#xfc;n&#xe7;</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Capecitabine-induced Coronary Artery Vasospasm in a Patient Who Previously Experienced a Similar Episode with Fluorouracil Therapy</article-title>. <source>Turk Kardiyol Dern Ars</source> <volume>44</volume> (<issue>1</issue>), <fpage>71</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.5543/tkda.2015.36005</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerr</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Segelov</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Falcon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hewett</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Adjuvant Capecitabine Plus Bevacizumab versus Capecitabine Alone in Patients with Colorectal Cancer (QUASAR 2): an Open-Label, Randomised Phase 3 Trial</article-title>. <source>Lancet Oncol.</source> <volume>17</volume> (<issue>11</issue>), <fpage>1543</fpage>&#x2013;<lpage>1557</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(16)30172-3</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Masood</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Husain</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Naeem</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>A Retrospective Study of Cardiotoxicities Induced by 5-fluouracil (5-FU) and 5-FU Based Chemotherapy Regimens in Pakistani Adult Cancer Patients at Shaukat Khanum Memorial Cancer Hospital &#x26; Research Center</article-title>. <source>J. Pak Med. Assoc.</source> <volume>62</volume> (<issue>5</issue>), <fpage>430</fpage>&#x2013;<lpage>434</lpage>. </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koca</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Salman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Unek</surname>
<given-names>I. T.</given-names>
</name>
<name>
<surname>Oztop</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ellidokuz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Eren</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Clinical and Electrocardiography Changes in Patients Treated with Capecitabine</article-title>. <source>Chemotherapy</source> <volume>57</volume> (<issue>5</issue>), <fpage>381</fpage>&#x2013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1159/000331645</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koopman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>N. F.</given-names>
</name>
<name>
<surname>Douma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wals</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Honkoop</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Erdkamp</surname>
<given-names>F. L.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Randomised Study of Sequential versus Combination Chemotherapy with Capecitabine, Irinotecan and Oxaliplatin in Advanced Colorectal Cancer, an Interim Safety Analysis. A Dutch Colorectal Cancer Group (DCCG) Phase III Study</article-title>. <source>Ann. Oncol.</source> <volume>17</volume> (<issue>10</issue>), <fpage>1523</fpage>&#x2013;<lpage>1528</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdl179</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosmas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kallistratos</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Kopterides</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Syrios</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Skopelitis</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mylonakis</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Cardiotoxicity of Fluoropyrimidines in Different Schedules of Administration: a Prospective Study</article-title>. <source>J. Cancer Res. Clin. Oncol.</source> <volume>134</volume> (<issue>1</issue>), <fpage>75</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-007-0250-9</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koutsoukis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ntalianis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Repasos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kastritis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dimopoulos</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Paraskevaidis</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cardio-oncology: A Focus on Cardiotoxicity</article-title>. <source>Eur. Cardiol.</source> <volume>13</volume> (<issue>1</issue>), <fpage>64</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.15420/ecr.2017:17:2</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurokawa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>New Aspects for the Treatment of Cardiac Diseases Based on the Diversity of Functional Controls on Cardiac Muscles: Acute Effects of Female Hormones on Cardiac Ion Channels and Cardiac Repolarization</article-title>. <source>J. Pharmacol. Sci.</source> <volume>109</volume> (<issue>3</issue>), <fpage>334</fpage>&#x2013;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1254/jphs.08r23fm</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwakman</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Simkens</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Mol</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>W. E.</given-names>
</name>
<name>
<surname>Koopman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Punt</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Incidence of Capecitabine-Related Cardiotoxicity in Different Treatment Schedules of Metastatic Colorectal Cancer: A Retrospective Analysis of the CAIRO Studies of the Dutch Colorectal Cancer Group</article-title>. <source>Eur. J. Cancer</source> <volume>76</volume>, <fpage>93</fpage>&#x2013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2017.02.009</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leicher</surname>
<given-names>L. W.</given-names>
</name>
<name>
<surname>de Graaf</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Coers</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tascilar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study</article-title>. <source>Drugs R. D</source> <volume>17</volume> (<issue>1</issue>), <fpage>117</fpage>&#x2013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1007/s40268-016-0154-8</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lestuzzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tartuferi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Viel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Buonadonna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vaccher</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Berretta</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare as it Seems</article-title>. <source>Oncologist</source> <volume>25</volume> (<issue>8</issue>), <fpage>e1254</fpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2020-0053</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lestuzzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vaccher</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Talamini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lleshi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meneguzzo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Viel</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Effort Myocardial Ischemia during Chemotherapy with 5-fluorouracil: an Underestimated Risk</article-title>. <source>Ann. Oncol.</source> <volume>25</volume> (<issue>5</issue>), <fpage>1059</fpage>&#x2013;<lpage>1064</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdu055</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ngorsuraches</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Risk Factors of Fluoropyrimidine Induced Cardiotoxicity Among Cancer Patients: A Systematic Review and Meta-Analysis</article-title>. <source>Crit. Rev. Oncology/Hematology</source> <volume>162</volume>, <fpage>103346</fpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2021.103346</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lordick</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lorenzen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stollfuss</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vehling-Kaiser</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kullmann</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hentrich</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Phase II Study of Weekly Oxaliplatin Plus Infusional Fluorouracil and Folinic Acid (FUFOX Regimen) as First-Line Treatment in Metastatic Gastric Cancer</article-title>. <source>Br. J. Cancer</source> <volume>93</volume> (<issue>2</issue>), <fpage>190</fpage>&#x2013;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6602697</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lotrionte</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biondi-Zoccai</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Abbate</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lanzetta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>D&#x27;Ascenzo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Malavasi</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity</article-title>. <source>Am. J. Cardiol.</source> <volume>112</volume> (<issue>12</issue>), <fpage>1980</fpage>&#x2013;<lpage>1984</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2013.08.026</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lounsbury</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Elokda</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Bunning</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>E. E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The Value of Detecting Asymptomatic Signs of Myocardial Ischemia in Patients with Coronary Artery Disease in Outpatient Cardiac Rehabilitation</article-title>. <source>J. Cardiovasc. Nurs.</source> <volume>32</volume> (<issue>3</issue>), <fpage>E1</fpage>&#x2013;<lpage>E9</lpage>. <pub-id pub-id-type="doi">10.1097/JCN.0000000000000380</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machiels</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Sempoux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scalliet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Coche</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Humblet</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Van Cutsem</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Phase I/II Study of Preoperative Cetuximab, Capecitabine, and External Beam Radiotherapy in Patients with Rectal Cancer</article-title>. <source>Ann. Oncol.</source> <volume>18</volume> (<issue>4</issue>), <fpage>738</fpage>&#x2013;<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdl460</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mambrini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanguinetti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pacetti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Caudana</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Iacono</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guglielmi</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Intra-arterial Infusion of 5-fluorouracil, Leucovorin, Epirubicin and Carboplatin (FLEC Regimen) in Unresectable Pancreatic Cancer: Results of a Ten-Year Experience</article-title>. <source>In Vivo</source> <volume>20</volume> (<issue>6A</issue>), <fpage>751</fpage>&#x2013;<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-04346-8_23</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mart&#xed;n</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Makhson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gligorov</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lichinitser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lluch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Semiglazov</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-Positive Locally Recurrent or Metastatic Breast Cancer</article-title>. <source>Oncologist</source> <volume>17</volume> (<issue>4</issue>), <fpage>469</fpage>&#x2013;<lpage>475</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2011-0344</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Loupakis</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Salvatore</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fornaro</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cremolini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cupini</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Bevacizumab with FOLFOXIRI (Irinotecan, Oxaliplatin, Fluorouracil, and Folinate) as First-Line Treatment for Metastatic Colorectal Cancer: a Phase 2 Trial</article-title>. <source>Lancet Oncol.</source> <volume>11</volume> (<issue>9</issue>), <fpage>845</fpage>&#x2013;<lpage>852</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(10)70175-3</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Arteaga</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Symmans</surname>
<given-names>W. F.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>B. H.</given-names>
</name>
<name>
<surname>Burnette</surname>
<given-names>B. L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy versus Capecitabine in Patients with Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131</article-title>. <source>J. Clin. Oncol.</source> <volume>39</volume> (<issue>23</issue>), <fpage>2539</fpage>&#x2013;<lpage>2551</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.21.00976</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Van Cutsem</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Falcone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Garcia-Carbonero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mizunuma</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer</article-title>. <source>N. Engl. J. Med.</source> <volume>372</volume> (<issue>20</issue>), <fpage>1909</fpage>&#x2013;<lpage>1919</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa1414325</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meydan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kundak</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yavuzsen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Oztop</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Barutca</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>U.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Cardiotoxicity of de Gramont&#x27;s Regimen: Incidence, Clinical Characteristics and Long-term Follow-up</article-title>. <source>Jpn. J. Clin. Oncol.</source> <volume>35</volume> (<issue>5</issue>), <fpage>265</fpage>&#x2013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1093/jjco/hyi071</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalaki</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fotiou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gennatas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gennatas</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Trastuzumab Plus Capecitabine and Docetaxel as First-Line Therapy for HER2-Positive Metastatic Breast Cancer: Phase II Results</article-title>. <source>Anticancer Res.</source> <volume>30</volume> (<issue>7</issue>), <fpage>3051</fpage>&#x2013;<lpage>3054</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2009.27.15_suppl.1111</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammed</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sallam</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>El-Abhar</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>P47885-Fluorouracil Cardiotoxicity: the Role of Oxidative Stress, Apoptosis, Inflammation and Endothelial Dysfuction</article-title>. <source>Eur. Heart J.</source> <volume>39</volume>, <fpage>1003</fpage>&#x2013;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehy563.P4788</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>More</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Asnani</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death</article-title>. <source>Curr. Cardiol. Rep.</source> <volume>23</volume> (<issue>3</issue>), <fpage>17</fpage>. <pub-id pub-id-type="doi">10.1007/s11886-021-01441-2</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>The Frequency and Pattern of Cardiotoxicity Observed with Capecitabine Used in Conjunction with Oxaliplatin in Patients Treated for Advanced Colorectal Cancer (CRC)</article-title>. <source>Eur. J. Cancer</source> <volume>41</volume> (<issue>11</issue>), <fpage>1542</fpage>&#x2013;<lpage>1546</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2005.03.027</pub-id> </citation>
</ref>
<ref id="B68">
<citation citation-type="book">
<collab>Nhlbi Study Quality Assessment Tools</collab> (<year>2020</year>). <source>National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)</source>. <publisher-loc>Bethesda, MD, USA</publisher-loc>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/healthtopics/study-quality-assessment-tools">https://www.nhlbi.nih.gov/healthtopics/study-quality-assessment-tools</ext-link> (accessed on February 10, 2020)</comment>. </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x27;Connell</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Colangelo</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Beart</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Petrelli</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Allegra</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Sharif</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points from National Surgical Adjuvant Breast and Bowel Project Trial R-04</article-title>. <source>J. Clin. Oncol.</source> <volume>32</volume> (<issue>18</issue>), <fpage>1927</fpage>&#x2013;<lpage>1934</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2013.53.7753</pub-id> </citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okines</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Langley</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Stenning</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Stevenson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Falk</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Bevacizumab with Peri-Operative Epirubicin, Cisplatin and Capecitabine (ECX) in Localised Gastro-Oesophageal Adenocarcinoma: a Safety Report</article-title>. <source>Ann. Oncol.</source> <volume>24</volume> (<issue>3</issue>), <fpage>702</fpage>&#x2013;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mds533</pub-id> </citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pai</surname>
<given-names>V. B.</given-names>
</name>
<name>
<surname>Nahata</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention</article-title>. <source>Drug Saf.</source> <volume>22</volume> (<issue>4</issue>), <fpage>263</fpage>&#x2013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.2165/00002018-200022040-00002</pub-id> </citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peiffert</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Giovannini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ducreux</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fran&#xe7;ois</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lemanski</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>High-dose Radiation Therapy and Neoadjuvant Plus Concomitant Chemotherapy with 5-fluorouracil and Cisplatin in Patients with Locally Advanced Squamous-Cell Anal Canal Cancer: Final Results of a Phase II Study</article-title>. <source>Ann. Oncol.</source> <volume>12</volume> (<issue>3</issue>), <fpage>397</fpage>&#x2013;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1023/A:1011107105538</pub-id> </citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Cardiotoxicity of 5-fluorouracil and Capecitabine in Chinese Patients: a Prospective Study</article-title>. <source>Cancer Commun. (Lond)</source> <volume>38</volume> (<issue>1</issue>), <fpage>22</fpage>. <pub-id pub-id-type="doi">10.1186/s40880-018-0292-1</pub-id> </citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lencioni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ricasoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iannopollo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Orlandini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oliveri</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Phase II Trial of Sorafenib in Combination with 5-fluorouracil Infusion in Advanced Hepatocellular Carcinoma</article-title>. <source>Cancer Chemother. Pharmacol.</source> <volume>69</volume> (<issue>3</issue>), <fpage>773</fpage>&#x2013;<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-011-1753-2</pub-id> </citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shahmarvand</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vistisen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vaage-Nilsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>F. O.</given-names>
</name>
<name>
<surname>Schou</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Incidence and Risk Factors for Capecitabine-Induced Symptomatic Cardiotoxicity: a Retrospective Study of 452 Consecutive Patients with Metastatic Breast Cancer</article-title>. <source>BMJ Open</source> <volume>6</volume>, <fpage>e012798</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2016-012798</pub-id> </citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Primrose</surname>
<given-names>J. N.</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>H. Z.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mirza</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Capecitabine Compared with Observation in Resected Biliary Tract Cancer (BILCAP): a Randomised, Controlled, Multicentre, Phase 3 Study</article-title>. <source>Lancet Oncol.</source> <volume>20</volume> (<issue>5</issue>), <fpage>663</fpage>&#x2013;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30915-X</pub-id> </citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raber</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Warack</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kanduri</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pribish</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Godishala</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abovich</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study</article-title>. <source>Oncologist</source> <volume>25</volume> (<issue>3</issue>), <fpage>E606</fpage>&#x2013;<lpage>E609</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2019-0762</pub-id> </citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sara</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Khodadadi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rehman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>5-fluorouracil and Cardiotoxicity: a Review</article-title>. <source>Ther. Adv. Med. Oncol.</source> <volume>10</volume>, <fpage>1758835918780140</fpage>. <pub-id pub-id-type="doi">10.1177/1758835918780140</pub-id> </citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saunders</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anwar</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Capecitabine-induced Myopericarditis - A Case Report and Review of Literature</article-title>. <source>J. Oncol. Pharm. Pract.</source> <volume>25</volume> (<issue>4</issue>), <fpage>1006</fpage>&#x2013;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.1177/1078155218774871</pub-id> </citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedhom</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sedhom</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>A Rare Case of Acute Coronary Syndrome Induced by Oral Capecitabine</article-title>. <source>Am. J. Resp. Crit. Care</source> <volume>195</volume>. <pub-id pub-id-type="doi">10.1016/S0735-1097(21)03914-0</pub-id> </citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skof</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rebersek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hlebanja</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ocvirk</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Capecitabine Plus Irinotecan (XELIRI Regimen) Compared to 5-FU/LV Plus Irinotecan (FOLFIRI Regimen) as Neoadjuvant Treatment for Patients with Unresectable Liver-Only Metastases of Metastatic Colorectal Cancer: a Randomised Prospective Phase II Trial</article-title>. <source>BMC Cancer</source> <volume>9</volume> (<issue>120</issue>), <fpage>120</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-9-120</pub-id> </citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Cornelius</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>Plummer</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Verrill</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Canney</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Cardiotoxicity of Anthracycline Agents for the Treatment of Cancer: Systematic Review and Meta-Analysis of Randomised Controlled Trials</article-title>. <source>BMC Cancer</source> <volume>10</volume>, <fpage>337</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-10-337</pub-id> </citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonyali</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Benekli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Coskun</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Ozkan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yildiz</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Efficacy and Toxicity of Trastuzumab and Paclitaxel Plus Capecitabine in the First-Line Treatment of HER2-Positive Metastatic Breast Cancer</article-title>. <source>J. Cancer Res. Clin. Oncol.</source> <volume>139</volume> (<issue>6</issue>), <fpage>981</fpage>&#x2013;<lpage>986</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-013-1409-1</pub-id> </citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsavaris</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kosmas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vadiaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Efremidis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zinelis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beldecos</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Cardiotoxicity Following Different Doses and Schedules of 5-fluorouracil Administration for Malignancy -- a Survey of 427 Patients</article-title>. <source>Med. Sci. Monit.</source> <volume>8</volume> (<issue>6</issue>), <fpage>PI51</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.12659/MSM.936523</pub-id> </citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Agac</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Aykan</surname>
<given-names>A. &#xc7;.</given-names>
</name>
<name>
<surname>Kul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aky&#xfc;z</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>G&#xf6;kdeniz</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Usefulness of Heart-type Fatty Acid-Binding Protein and Myocardial Performance Index for Early Detection of 5-Fluorouracil Cardiotoxicity</article-title>. <source>Angiology</source> <volume>68</volume> (<issue>1</issue>), <fpage>52</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1177/0003319716637516</pub-id> </citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaishampayan</surname>
<given-names>U. N.</given-names>
</name>
<name>
<surname>Ben-Josef</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Philip</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Vaitkevicius</surname>
<given-names>V. K.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>K. J.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>A Single-Institution Experience with Concurrent Capecitabine and Radiation Therapy in Gastrointestinal Malignancies</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source> <volume>53</volume>, <fpage>675</fpage>&#x2013;<lpage>679</lpage>. <comment>(PII S0360-9(02)02772-43)</comment>. <pub-id pub-id-type="doi">10.1016/S0360-3016(02)02772-4</pub-id> </citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Cutsem</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hoff</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Abt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Osterwalder</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Incidence of Cardiotoxicity with the Oral Fluoropyrimidine Capecitabine Is Typical of that Reported with 5-fluorouracil</article-title>. <source>Ann. Oncol.</source> <volume>13</volume>, <fpage>484</fpage>&#x2013;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdf108</pub-id> </citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wacker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lersch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scherpinski</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Reindl</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Seyfarth</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>High Incidence of Angina Pectoris in Patients Treated with 5-fluorouracil. A Planned Surveillance Study with 102 Patients</article-title>. <source>ONCOLOGY</source> <volume>65</volume> (<issue>2</issue>), <fpage>108</fpage>&#x2013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1159/000072334</pub-id> </citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winther</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Zubcevic</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Qvortrup</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vestermark</surname>
<given-names>L. W.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Krogh</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Experience with S-1 in Older Caucasian Patients with Metastatic Colorectal Cancer (mCRC): Findings from an Observational Chart Review</article-title>. <source>Acta Oncol.</source> <volume>55</volume> (<issue>7</issue>), <fpage>881</fpage>&#x2013;<lpage>885</lpage>. <pub-id pub-id-type="doi">10.3109/0284186X.2016.1161825</pub-id> </citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Iwase</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kitamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Odagiri</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nagumo</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>A Phase II Study of Trastuzumab and Capecitabine for Patients with HER2-Overexpressing Metastatic Breast Cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial</article-title>. <source>Cancer Chemother. Pharmacol.</source> <volume>61</volume> (<issue>3</issue>), <fpage>509</fpage>&#x2013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-007-0497-5</pub-id> </citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yerushalmi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Idelevich</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dror</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stemmer</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Figer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sulkes</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Preoperative Chemoradiation in Rectal Cancer: Retrospective Comparison between Capecitabine and Continuous Infusion of 5-fluorouracil</article-title>. <source>J. Surg. Oncol.</source> <volume>93</volume> (<issue>7</issue>), <fpage>529</fpage>&#x2013;<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1002/jso.20503</pub-id> </citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Oztop</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ciloglu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Okan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tekin</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Yaren</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>5-Fluorouracil Increases the Number and Complexity of Premature Complexes in the Heart: a Prospective Study Using Ambulatory ECG Monitoring</article-title>. <source>Int. J. Clin. Pract.</source> <volume>61</volume> (<issue>5</issue>), <fpage>795</fpage>&#x2013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-1241.2007.01323.x</pub-id> </citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zafar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Drobni</surname>
<given-names>Z. D.</given-names>
</name>
<name>
<surname>Mosarla</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Alvi</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>U. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The Incidence, Risk Factors, and Outcomes with 5-Fluorouracil-Associated Coronary Vasospasm</article-title>. <source>JACC CardioOncol</source> <volume>3</volume> (<issue>1</issue>), <fpage>101</fpage>&#x2013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaccao.2020.12.005</pub-id> </citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Utidelone Plus Capecitabine versus Capecitabine Alone for Heavily Pretreated Metastatic Breast Cancer Refractory to Anthracyclines and Taxanes: a Multicentre, Open-Label, Superiority, Phase 3, Randomised Controlled Trial</article-title>. <source>Lancet Oncol.</source> <volume>18</volume> (<issue>3</issue>), <fpage>371</fpage>&#x2013;<lpage>383</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30088-8</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>